[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Bion Enterprises Ltd\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":410},{"warningLetters":4,"total":409},[5,30,54,75,94,114,134,156,180,200,220,239,260,280,299,322,340,358,374,391],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},812,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-24T04:00:00Z\">06\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmom-enterprises-llc-698651-04222025\">M.O.M. Enterprises, LLC\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yasmin S. Kaderali\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>M.O.M. Enterprises, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 Canal Boulevard, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Ykaderali@mommysbliss.com\"> Ykaderali@mommysbliss.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 22, 2025&nbsp;\u003C\u002Fp>\u003Cp>RE: CMS 698651\u003C\u002Fp>\u003Cp>Dear Ms. Kaderali:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your dietary supplement facility located at 1001 Canal Boulevard, Suite C, Richmond, California 94804, from August 19 through September 27, 2024. Based on inspectional findings and a review of your product labels collected during the inspection, as well as a review of your firm’s website, www.mommysbliss.com, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You may find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on September 27, 2024, our investigator provided your firm with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated October 17 and November 22, 2024, and January 10, 2025; we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from August 19 through September 27, 2024, identified serious violations of FDA’s regulations for current Good Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21 of the Code of Federal Regulations, Part 111 (21 CFR 111). These violations cause your dietary supplement products Gripe Water Original, Gripe Water Night Time, Kids Cough Syrup &amp; Mucus + Immunity Support, and Kids Cough Syrup &amp; Mucus Night Time (including such product in the Day + Night Combo Packs) to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the cGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to extend the review and investigation of a product complaint to all relevant batchesand records, as required by 21 CFR 111.560(c).\u003C\u002Fp>\u003Cp>You initiated a market withdrawal of eight lots of Kids Cough Syrup &amp; Mucus + ImmunitySupport, Kids Cough Syrup &amp; Mucus Night Time, Baby Cough Syrup &amp; Mucus + ImmunitySupport, and Baby Cough Syrup &amp; Mucus Nighttime, including those in the Day + Night Combo Packs, on April 19, 2023, after your contract manufacturer notified you of early spoilage in these products. You reformulated the product to include the addition of glycerin to lower the water activity and also lowered the pH of the products, but your investigation did not extend to all relevant batches and records. After your firm initiated the market withdrawal, you received at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints from September 2023 through May 2024, in which complainants described bulging bottles of product and product where the lids popped off, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints for Kids Cough Syrup &amp; Mucus Night Time, Lot Number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, EXP 03\u002F25, which lot was not included in your market withdrawal. For example, complaint #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, received on December 1, 2023, for Kids Cough Syrup &amp; Mucus Night Time, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, stated that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and described “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Relating to this complaint, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>. The product has since reformulated the product [\u003Cem>sic\u003C\u002Fem>].” Your investigation, however, does not explain how such reformulation would have addressed the issue relating to bulging product bottles and product packaging that popped open, nor did it address the concerns relating to this specific lot that had not been withdrawn from the market.\u003C\u002Fp>\u003Cp>In your October 17, 2024, response, you indicate the mold complaints were not new problems and were part of a previously investigated issue. However, your response does not explain how you determined that the issues were connected to complaints you received subsequent to the market withdrawal. You did not conduct additional investigations of these complaints to determine whether additional lots of product were affected by the known spoilage issue to determine if additional corrective actions were needed, even though your complaint records correlate these complaints to your market withdrawal.\u003C\u002Fp>\u003Cp>2. You failed to follow written procedures for the requirements to review and investigate all product complaints, as required by 21 CFR 111.553. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure, revision date March 14, 2019, SOP #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure, effective date July 1, 2022, QA-1009, both require your quality control manager to review complaints to determine whether the complaint involves a possible failure of a dietary supplement to meet any of its specifications, and to review and approve decisions to investigate complaints and any findings and follow up actions, in accordance with 21 CFR 111.560(a) and 21 CFR 111.560(b). However, a review of complaints you received from December 2019 through August 2024 revealed complaints that were not investigated. For example:\u003C\u002Fp>\u003Cp>a. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” revealed there were \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints that were not investigated, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which met the criteria for a serious adverse event.\u003C\u002Fp>\u003Cp>b. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” revealed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints that were not investigated. Of these \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were resolved as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with no further action documented.\u003C\u002Fp>\u003Cp>In your October 17, 2024, response, you committed to updating your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and conducting a retrospective review of all complaints received from 2019-2024 to ensure all are fully investigated and completely documented. You also indicated that any complaints that are determined to be a serious adverse event will be reported per your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure, and that you will conduct retraining of your employees on the revised procedure, as well as perform monthly monitoring of your firm’s compliance with the revised procedure.\u003C\u002Fp>\u003Cp>In your response dated November 22, 2024, you provided a copy of your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and stated that your employee retraining was completed on November 20, 2024. You also indicated your retrospective review of complaints is in-progress. As your corrective actions are still in progress, we cannot evaluate the adequacy of your corrections at this time.\u003C\u002Fp>\u003Cp>3. You failed to comply with the requirements for records of product complaints in 21 CFR111.570. Specifically, written records of product complaints that are related to good manufacturing practice must include the findings of the investigation and follow-up action taken when an investigation is performed [21 CFR 111.570(b)(2)(ii)(F)]. However, a review of your electronic consumer complaint records revealed your complaint records, in which your Quality Manager stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, complaint #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, received October 4, 2021, in which the complainant described their baby turning blue after administering Gripe Water Night Time, your electronic record indicates the quality investigation is completed. However, you were unable to provide documentation pertaining to the quality review and investigation of this complaint.\u003C\u002Fp>\u003Cp>In your initial response, you committed to revising your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and including a detailed template which will be designed to capture all required steps and follow-up actions for complaint investigations. You provided FDA with this revised procedure and the consumer complaint investigation form. We will evaluate the adequacy of this corrective action during our next inspection of your firm.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Failure to Submit a Serious Adverse Event Report\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to submit a Serious Adverse Event Report (SAER) for a dietary supplement within 15 business days after receiving a report about the adverse event, as required by section 761(c) of the Act [21 U.S.C. 379aa-1(c)]. Specifically, you received reports of at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> serious adverse events between December 2019 and August 2024, but did not submit a SAER as required. For example, our inspection found you received reports of infants choking, infants that stopped breathing, and infants that were admitted to the hospital after being administered your Gripe Water Original products. For example:\u003C\u002Fp>\u003Cp>a. On January 19, 2021, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described giving their two-month-old baby Gripe Water Original on January 12, 2021, and a second dose on January 13, 2021, when they noticed he had a fever of 101.8 degrees. The complainant explained they called the local emergency room which advised the complainant to bring the baby to the hospital. The complainant explained their baby was sent to a bigger hospital where additional tests, including blood work and a spinal tap were performed and he was admitted to the hospital where he stayed until January 17, 2021. Per the complainant, the tests were positive for E. coli, although the complainant reported the hospital could not tell them what caused the infection.\u003C\u002Fp>\u003Cp>b. On October 7, 2021, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described their daughter was born prematurely, they used Gripe Water Original and the infant vomited and was taken to the emergency room. The complainant further explained the infant “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>c. On October 15, 2021, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described their six-week-old infant choked on Gripe Water Original. Per your complaint record, the complainant explained their infant “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Your complaint record further explains the complainant attempted cardiopulmonary resuscitation (CPR) multiple times until the infant began breathing again. The complainant also reported that paramedics were called and looked over their infant.\u003C\u002Fp>\u003Cp>d. On March 30, 2022, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant gave their baby Gripe Water Original and the baby “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The complainant further explained they were “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>e. On May 4, 2023, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described giving their baby Gripe Water Original and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>f. On July 30, 2024, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described their child choking on Gripe Water Original on two different occasions. The complainant explained they gave their two-month-old some Gripe Water Original, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>Under section 761(c) of the Act, you must submit a report of a serious adverse event associated with any of your dietary supplements no later than fifteen (15) business days after a report of the event is received through the address or phone number provided on your dietary supplement products.\u003C\u002Fp>\u003Cp>Because prompt submission of such serious adverse event reports is important for public health reasons, the agency recommends that all serious adverse events be reported to FDA within fifteen (15) business days of receipt regardless of the means by which you receive the initial report. These serious adverse event reports should be submitted under the MedWatch Form 3500A. More information on adverse event reporting can be found on FDA’s website at www.fda.gov, in the publication “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act.”\u003C\u002Fp>\u003Cp>In your written response letters, with respect to the observation relating to serious adverse event reporting, you provided a revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and complaint investigation form that appear to provide adequate details for assessing the severity of the adverse events. You also committed to conducting a retrospective review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints identified during our inspection as reportable events using your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and reporting any complaints that are deemed reportable.\u003C\u002Fp>\u003Cp>In your October 17, 2024, response, you quote from the guidance “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act” and explain that you interpreted the FDA guidance as stating the details of the event come from the perspective of trained health care professionals. However, FDA’s guidance clearly states, as quoted in your response, “[W]e encourage responsible persons to use trained health care practitioners to elicit information from reporters, computer-assisted interview technology, targeted questionnaires, and\u002For other appropriate methods that help focus the line of questioning.” It does not appear that your firm was using either trained healthcare professionals, computer-assisted interview technology, targeted questionnaires, or other methods that would help focus the line of questioning; your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure required customer service representatives to determine whether a complaint required escalation as an adverse event or serious adverse event. It is not a requirement that the details of events come from trained healthcare professionals; it does not require “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as stated in your response. In fact, the guidance defines an initial reporter as the person who first notifies the responsible person about the serious adverse event and “can be the patient, a family member, or some other person (e.g., doctor, pharmacist).”\u003C\u002Fp>\u003Cp>According to your November 22, 2024, response, as a result of your retrospective review of the complaints identified during our inspection, you are in the process of reporting \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the complaints to FDA as SAERs, and are re-opening the remaining complaints for one year in order to try and gather additional information needed for reporting the SAERs. Per your response, you have concluded these remaining complaints are also qualifying events per your procedure, but do not have complete data elements.\u003C\u002Fp>\u003Cp>Of the remaining complaints that you identified as qualifying events, the missing data element for many of these complaints is listed as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, per the complaint records reviewed during our inspection, the product name is identified as Gripe Water Original for each of these complaints. It is unclear why the complaint records reviewed during our inspection identified the product as “Gripe Water Original” for each of these complaints, but your retrospective review has now determined the complainant didn’t specify the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. Your Gripe Water, Gripe Water Night Time, and Kids Cough Syrup &amp; Mucus Day + Night Combo Pack products are misbranded within the meaning of section 403(q)(5)(F) [21 U.S.C. 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.9, 21 CFR 101.36, and 21 CFR 101.2. For example:\u003C\u002Fp>\u003Cp>a. The product’s inner bottle labels do not bear nutrition information, as required by 21 CFR 101.36. The unit container is exempted from these requirements if the unit container bears the statement “This Unit Not Labeled for Retail Sale” [21 CFR 1.24(a)(24)].\u003C\u002Fp>\u003Cp>b. The dosage guide and\u002For directions for use are placed above the Supplement Facts label, which is not in accordance with 21 CFR 101.2(a) and (e). Nutrition information should appear on the principal display panel (PDP) or directly to the right of the PDP with no intervening material in between.\u003C\u002Fp>\u003Cp>c. For your Gripe Water Night Time and Kids Cough Syrup &amp; Mucus Day + Night Combo Pack, the serving size in the Supplement Facts labels fails to be declared as required by 21 CFR 101.36(b)(1)(i). Serving size must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your website at the internet address www.mommysbliss.com in December 2024 and determined that you take orders there for your Gripe Water Original. The claims on your website establish that your product Gripe Water Original is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. Thus, in addition to being an adulterated and misbranded dietary supplement, your Gripe Water Original is also an unapproved new drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)].\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your Gripe Water Original product is intended for use as a drug include:\u003C\u002Fp>\u003Cp>From the blog post on your website: Acid Reflux = The Pits – Mommy's Bliss\u003C\u002Fp>\u003Cp>• &nbsp;“Acid reflux, also known as gastroesophageal reflux or GER, is when acids and content of the stomach come back up into the baby’s esophagus. It happens because the lower esophageal sphincter isn’t fully developed. . . .[I]f [a baby’s esophageal sphincter] fails to develop correctly or becomes weak, a baby may develop GERD (gastroesophageal reflux disease) which has more severe complications. . . .\u003C\u002Fp>\u003Cp>How do you know if your baby has acid reflux?&nbsp;&nbsp;\u003Cbr>The symptoms of acid reflux are typically clear and easy to read….&nbsp;\u003C\u002Fp>\u003Cp>1. Frequent Vomiting….2. Irritability….The acid of the digestive juices irritates the stomach and esophagus….3. Persistent Coughing or Wheezing….There is a link between acid reflux, wheezing, coughing, and even asthma….5. Colic The persistent crying of a colicky baby could be a symptom of reflux. The irritation of the stomach and the esophagus from all those digestive juices may trigger your baby into colic….How do you help a baby with acid reflux?....&nbsp;\u003C\u002Fp>\u003Cp>Try Gripe Water&nbsp;\u003C\u002Fp>\u003Cp>Gripe water can also be a great way to ease symptoms of acid reflux in infants. It is a natural approach to help reduce the stomach acid that causes pain. . . .&nbsp;\u003C\u002Fp>\u003Cp>Mommy’s Bliss Gripe Water is a safe and gentle way to help ease your baby’s stomach discomfort. The organic ginger and fennel relieve the irritation and prevent the stomach acid from flowing up into the esophagus. Fennel is known for its ability to reduce inflammation and acid in the stomach while ginger’s phenolic compounds help relieve irritation and reduce gastric contractions.”\u003C\u002Fp>\u003Cp>Additionally, your blog post titled “Acid Reflux = The Pits,” in discussing the “link between acid reflex, wheezing, and coughing,” links to an article from the Mayo Clinic article entitled “Asthma and acid reflux: Are they linked?” (Asthma and acid reflux: Are they linked? - Mayo Clinic). This link from your blog further suggests that your Mommy’s Bliss Gripe Water Original is intended for the cure, mitigation, treatment, or prevention of GERD and asthma.\u003C\u002Fp>\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safety and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your Gripe Water Original is intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Gripe Water Original fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response should be sent to Jamie M. Bumpas, Compliance Officer, U.S. Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835, or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. If you have any questions, you may email us at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #698651 on any submissions and within the subject line of any \u003Ca>emails.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Sincerely,&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F&nbsp;\u003Cbr>Laura Akowuah, JD, MPH&nbsp;&nbsp;\u003Cbr>Acting Director, Office of Enforcement&nbsp;&nbsp;\u003Cbr>Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>Human Foods Program&nbsp;&nbsp;\u003Cbr>U.S. Food and Drug Administration\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYasmin S. Kaderali\n\nRecipient Title\n\nOwner and CEO\n\nM.O.M. Enterprises, LLC\n\n1001 Canal Boulevard, Suite C\n\nRichmond, CA 94804\n\nUnited States\n\nYkaderali@mommysbliss.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nApril 22, 2025\nRE: CMS 698651\nDear Ms. Kaderali:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your dietary supplement facility located at 1001 Canal Boulevard, Suite C, Richmond, California 94804, from August 19 through September 27, 2024. Based on inspectional findings and a review of your product labels collected during the inspection, as well as a review of your firm’s website, www.mommysbliss.com, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You may find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on September 27, 2024, our investigator provided your firm with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated October 17 and November 22, 2024, and January 10, 2025; we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility from August 19 through September 27, 2024, identified serious violations of FDA’s regulations for current Good Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21 of the Code of Federal Regulations, Part 111 (21 CFR 111). These violations cause your dietary supplement products Gripe Water Original, Gripe Water Night Time, Kids Cough Syrup & Mucus + Immunity Support, and Kids Cough Syrup & Mucus Night Time (including such product in the Day + Night Combo Packs) to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\nYour significant violations of the cGMP requirements are as follows:\n1. You failed to extend the review and investigation of a product complaint to all relevant batchesand records, as required by 21 CFR 111.560(c).\nYou initiated a market withdrawal of eight lots of Kids Cough Syrup & Mucus + ImmunitySupport, Kids Cough Syrup & Mucus Night Time, Baby Cough Syrup & Mucus + ImmunitySupport, and Baby Cough Syrup & Mucus Nighttime, including those in the Day + Night Combo Packs, on April 19, 2023, after your contract manufacturer notified you of early spoilage in these products. You reformulated the product to include the addition of glycerin to lower the water activity and also lowered the pH of the products, but your investigation did not extend to all relevant batches and records. After your firm initiated the market withdrawal, you received at least (b)(4) complaints from September 2023 through May 2024, in which complainants described bulging bottles of product and product where the lids popped off, including (b)(4) complaints for Kids Cough Syrup & Mucus Night Time, Lot Number (b)(4), EXP 03\u002F25, which lot was not included in your market withdrawal. For example, complaint #(b)(4), received on December 1, 2023, for Kids Cough Syrup & Mucus Night Time, lot number (b)(4), stated that “(b)(4)” and described “(b)(4).” Relating to this complaint, your “(b)(4)” states, “(b)(4). The product has since reformulated the product [sic].” Your investigation, however, does not explain how such reformulation would have addressed the issue relating to bulging product bottles and product packaging that popped open, nor did it address the concerns relating to this specific lot that had not been withdrawn from the market.\nIn your October 17, 2024, response, you indicate the mold complaints were not new problems and were part of a previously investigated issue. However, your response does not explain how you determined that the issues were connected to complaints you received subsequent to the market withdrawal. You did not conduct additional investigations of these complaints to determine whether additional lots of product were affected by the known spoilage issue to determine if additional corrective actions were needed, even though your complaint records correlate these complaints to your market withdrawal.\n2. You failed to follow written procedures for the requirements to review and investigate all product complaints, as required by 21 CFR 111.553. Your “(b)(4)” procedure, revision date March 14, 2019, SOP #(b)(4), and your “(b)(4)” procedure, effective date July 1, 2022, QA-1009, both require your quality control manager to review complaints to determine whether the complaint involves a possible failure of a dietary supplement to meet any of its specifications, and to review and approve decisions to investigate complaints and any findings and follow up actions, in accordance with 21 CFR 111.560(a) and 21 CFR 111.560(b). However, a review of complaints you received from December 2019 through August 2024 revealed complaints that were not investigated. For example:\na. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “(b)(4)” revealed there were (b)(4) complaints that were not investigated, (b)(4) of which met the criteria for a serious adverse event.\nb. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “(b)(4),” “(b)(4),” and “(b)(4)” revealed at least (b)(4) complaints that were not investigated. Of these (b)(4) complaints, (b)(4) were resolved as “(b)(4)” with no further action documented.\nIn your October 17, 2024, response, you committed to updating your (b)(4) procedure and conducting a retrospective review of all complaints received from 2019-2024 to ensure all are fully investigated and completely documented. You also indicated that any complaints that are determined to be a serious adverse event will be reported per your revised (b)(4) procedure, and that you will conduct retraining of your employees on the revised procedure, as well as perform monthly monitoring of your firm’s compliance with the revised procedure.\nIn your response dated November 22, 2024, you provided a copy of your revised (b)(4) procedure and stated that your employee retraining was completed on November 20, 2024. You also indicated your retrospective review of complaints is in-progress. As your corrective actions are still in progress, we cannot evaluate the adequacy of your corrections at this time.\n3. You failed to comply with the requirements for records of product complaints in 21 CFR111.570. Specifically, written records of product complaints that are related to good manufacturing practice must include the findings of the investigation and follow-up action taken when an investigation is performed [21 CFR 111.570(b)(2)(ii)(F)]. However, a review of your electronic consumer complaint records revealed your complaint records, in which your Quality Manager stated that (b)(4). For example, complaint #(b)(4), received October 4, 2021, in which the complainant described their baby turning blue after administering Gripe Water Night Time, your electronic record indicates the quality investigation is completed. However, you were unable to provide documentation pertaining to the quality review and investigation of this complaint.\nIn your initial response, you committed to revising your (b)(4) procedure and including a detailed template which will be designed to capture all required steps and follow-up actions for complaint investigations. You provided FDA with this revised procedure and the consumer complaint investigation form. We will evaluate the adequacy of this corrective action during our next inspection of your firm.\nFailure to Submit a Serious Adverse Event Report\nYou failed to submit a Serious Adverse Event Report (SAER) for a dietary supplement within 15 business days after receiving a report about the adverse event, as required by section 761(c) of the Act [21 U.S.C. 379aa-1(c)]. Specifically, you received reports of at least (b)(4) serious adverse events between December 2019 and August 2024, but did not submit a SAER as required. For example, our inspection found you received reports of infants choking, infants that stopped breathing, and infants that were admitted to the hospital after being administered your Gripe Water Original products. For example:\na. On January 19, 2021, you received a complaint (#(b)(4)) in which the complainant described giving their two-month-old baby Gripe Water Original on January 12, 2021, and a second dose on January 13, 2021, when they noticed he had a fever of 101.8 degrees. The complainant explained they called the local emergency room which advised the complainant to bring the baby to the hospital. The complainant explained their baby was sent to a bigger hospital where additional tests, including blood work and a spinal tap were performed and he was admitted to the hospital where he stayed until January 17, 2021. Per the complainant, the tests were positive for E. coli, although the complainant reported the hospital could not tell them what caused the infection.\nb. On October 7, 2021, you received a complaint (#(b)(4)) in which the complainant described their daughter was born prematurely, they used Gripe Water Original and the infant vomited and was taken to the emergency room. The complainant further explained the infant “(b)(4).”\nc. On October 15, 2021, you received a complaint (#(b)(4)) in which the complainant described their six-week-old infant choked on Gripe Water Original. Per your complaint record, the complainant explained their infant “(b)(4).” Your complaint record further explains the complainant attempted cardiopulmonary resuscitation (CPR) multiple times until the infant began breathing again. The complainant also reported that paramedics were called and looked over their infant.\nd. On March 30, 2022, you received a complaint (#(b)(4)) in which the complainant gave their baby Gripe Water Original and the baby “(b)(4).” The complainant further explained they were “(b)(4).”\ne. On May 4, 2023, you received a complaint (#(b)(4)) in which the complainant described giving their baby Gripe Water Original and “(b)(4).”\nf. On July 30, 2024, you received a complaint (#(b)(4)) in which the complainant described their child choking on Gripe Water Original on two different occasions. The complainant explained they gave their two-month-old some Gripe Water Original, “(b)(4).”\nUnder section 761(c) of the Act, you must submit a report of a serious adverse event associated with any of your dietary supplements no later than fifteen (15) business days after a report of the event is received through the address or phone number provided on your dietary supplement products.\nBecause prompt submission of such serious adverse event reports is important for public health reasons, the agency recommends that all serious adverse events be reported to FDA within fifteen (15) business days of receipt regardless of the means by which you receive the initial report. These serious adverse event reports should be submitted under the MedWatch Form 3500A. More information on adverse event reporting can be found on FDA’s website at www.fda.gov, in the publication “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act.”\nIn your written response letters, with respect to the observation relating to serious adverse event reporting, you provided a revised (b)(4) procedure and complaint investigation form that appear to provide adequate details for assessing the severity of the adverse events. You also committed to conducting a retrospective review of the (b)(4) complaints identified during our inspection as reportable events using your revised (b)(4) procedure and reporting any complaints that are deemed reportable.\nIn your October 17, 2024, response, you quote from the guidance “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act” and explain that you interpreted the FDA guidance as stating the details of the event come from the perspective of trained health care professionals. However, FDA’s guidance clearly states, as quoted in your response, “[W]e encourage responsible persons to use trained health care practitioners to elicit information from reporters, computer-assisted interview technology, targeted questionnaires, and\u002For other appropriate methods that help focus the line of questioning.” It does not appear that your firm was using either trained healthcare professionals, computer-assisted interview technology, targeted questionnaires, or other methods that would help focus the line of questioning; your (b)(4) procedure required customer service representatives to determine whether a complaint required escalation as an adverse event or serious adverse event. It is not a requirement that the details of events come from trained healthcare professionals; it does not require “(b)(4)” as stated in your response. In fact, the guidance defines an initial reporter as the person who first notifies the responsible person about the serious adverse event and “can be the patient, a family member, or some other person (e.g., doctor, pharmacist).”\nAccording to your November 22, 2024, response, as a result of your retrospective review of the complaints identified during our inspection, you are in the process of reporting (b)(4) of the complaints to FDA as SAERs, and are re-opening the remaining complaints for one year in order to try and gather additional information needed for reporting the SAERs. Per your response, you have concluded these remaining complaints are also qualifying events per your procedure, but do not have complete data elements.\nOf the remaining complaints that you identified as qualifying events, the missing data element for many of these complaints is listed as “(b)(4).” However, per the complaint records reviewed during our inspection, the product name is identified as Gripe Water Original for each of these complaints. It is unclear why the complaint records reviewed during our inspection identified the product as “Gripe Water Original” for each of these complaints, but your retrospective review has now determined the complainant didn’t specify the product.\nMisbranded Dietary Supplements\n1. Your Gripe Water, Gripe Water Night Time, and Kids Cough Syrup & Mucus Day + Night Combo Pack products are misbranded within the meaning of section 403(q)(5)(F) [21 U.S.C. 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.9, 21 CFR 101.36, and 21 CFR 101.2. For example:\na. The product’s inner bottle labels do not bear nutrition information, as required by 21 CFR 101.36. The unit container is exempted from these requirements if the unit container bears the statement “This Unit Not Labeled for Retail Sale” [21 CFR 1.24(a)(24)].\nb. The dosage guide and\u002For directions for use are placed above the Supplement Facts label, which is not in accordance with 21 CFR 101.2(a) and (e). Nutrition information should appear on the principal display panel (PDP) or directly to the right of the PDP with no intervening material in between.\nc. For your Gripe Water Night Time and Kids Cough Syrup & Mucus Day + Night Combo Pack, the serving size in the Supplement Facts labels fails to be declared as required by 21 CFR 101.36(b)(1)(i). Serving size must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\nUnapproved New Drug\nFDA reviewed your website at the internet address www.mommysbliss.com in December 2024 and determined that you take orders there for your Gripe Water Original. The claims on your website establish that your product Gripe Water Original is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. Thus, in addition to being an adulterated and misbranded dietary supplement, your Gripe Water Original is also an unapproved new drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)].\nExamples of some of the claims that provide evidence that your Gripe Water Original product is intended for use as a drug include:\nFrom the blog post on your website: Acid Reflux = The Pits – Mommy's Bliss\n• “Acid reflux, also known as gastroesophageal reflux or GER, is when acids and content of the stomach come back up into the baby’s esophagus. It happens because the lower esophageal sphincter isn’t fully developed. . . .[I]f [a baby’s esophageal sphincter] fails to develop correctly or becomes weak, a baby may develop GERD (gastroesophageal reflux disease) which has more severe complications. . . .\nHow do you know if your baby has acid reflux?\nThe symptoms of acid reflux are typically clear and easy to read….\n1. Frequent Vomiting….2. Irritability….The acid of the digestive juices irritates the stomach and esophagus….3. Persistent Coughing or Wheezing….There is a link between acid reflux, wheezing, coughing, and even asthma….5. Colic The persistent crying of a colicky baby could be a symptom of reflux. The irritation of the stomach and the esophagus from all those digestive juices may trigger your baby into colic….How do you help a baby with acid reflux?....\nTry Gripe Water\nGripe water can also be a great way to ease symptoms of acid reflux in infants. It is a natural approach to help reduce the stomach acid that causes pain. . . .\nMommy’s Bliss Gripe Water is a safe and gentle way to help ease your baby’s stomach discomfort. The organic ginger and fennel relieve the irritation and prevent the stomach acid from flowing up into the esophagus. Fennel is known for its ability to reduce inflammation and acid in the stomach while ginger’s phenolic compounds help relieve irritation and reduce gastric contractions.”\nAdditionally, your blog post titled “Acid Reflux = The Pits,” in discussing the “link between acid reflex, wheezing, and coughing,” links to an article from the Mayo Clinic article entitled “Asthma and acid reflux: Are they linked?” (Asthma and acid reflux: Are they linked? - Mayo Clinic). This link from your blog further suggests that your Mommy’s Bliss Gripe Water Original is intended for the cure, mitigation, treatment, or prevention of GERD and asthma.\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drug\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safety and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour Gripe Water Original is intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Gripe Water Original fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written response should be sent to Jamie M. Bumpas, Compliance Officer, U.S. Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835, or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. If you have any questions, you may email us at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #698651 on any submissions and within the subject line of any emails.\nSincerely,\n\u002FS\u002F\nLaura Akowuah, JD, MPH\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\nU.S. Food and Drug Administration","M.O.M. Enterprises, LLC","mom-enterprises-llc-698651-04222025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmom-enterprises-llc-698651-04222025","2026-10-26T08:09:27.535097+00:00","Warning Letter","Issued","2025-06-24","698651","Food & Beverages","Yasmin S. Kaderali","2026-08-19T16:39:01.029+00:00","2025-04-22",{"id":31,"raw":32,"subject":37,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":46,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":50,"issuing_office":36,"recipient_name":51,"body_fetched_at":52,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1508,[33,34,35,36,37,13,38,13],"\u003Ctime datetime=\"2024-04-23T13:20:00Z\">04\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-18T04:00:00Z\">04\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzen-enterprises-llc-678407-04182024\">Zen Enterprises LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Register and List","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzen-enterprises-llc-678407-09112024\">\u003Ctime datetime=\"2024-09-17T04:00:00Z\">09\u002F17\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Makima\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Zen Enterprises LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9061 W. Sahara Ste 105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>98117-5797\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Registration@fdaimports.com\"> Registration@fdaimports.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 18, 2024\u003Cbr>\n\u003Cbr>\nRE: WL 2644\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Makima:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&amp;C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003, the manufacturer referenced under the establishment section of the listing SPL files is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided on December 15, 2022 to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not currently involved in the manufacturing of the drugs mentioned above. Thus, Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. should not be registered with FDA as a manufacturer, nor should this firm be included as the manufacturer under the establishment sections of any drug listing files. To date, no updates have been made to the listing files to correct the manufacturer that is referenced.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003 are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products included above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003Cbr>\n\u003Cbr>\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2644 on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid Makima\n\nZen Enterprises LLC\n\n9061 W. Sahara Ste 105\n\nLas Vegas, NV 98117-5797\n\nUnited States\n\nRegistration@fdaimports.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nApril 18, 2024\n\nRE: WL 2644\n\nDear Mr. Makima:\n\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003.1 Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nRegistration and Drug Listing Violations\n\nSection 510(j) of the FD&C Act, 21 U.S.C 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003, the manufacturer referenced under the establishment section of the listing SPL files is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided on December 15, 2022 to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not currently involved in the manufacturing of the drugs mentioned above. Thus, Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. should not be registered with FDA as a manufacturer, nor should this firm be included as the manufacturer under the establishment sections of any drug listing files. To date, no updates have been made to the listing files to correct the manufacturer that is referenced.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003 are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products included above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2644 on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________________\n\n1 On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).","Zen Enterprises LLC","zen-enterprises-llc-678407-04182024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzen-enterprises-llc-678407-04182024","2026-10-26T08:10:38.406573+00:00","Closed Out","2024-04-23","678407","Drugs","2024-09-17","David Makima","2026-08-20T00:10:11.347+00:00","2024-04-18",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":26,"closeout_date":19,"issuing_office":60,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":74,"medical_device_id":19,"response_letter_date":19},21711,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-13T04:00:00Z\">08\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbo-wah-enterprises-inc-736539-08132026\">Bo Wah Enterprises Inc\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Danny Y.W. Au\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bo Wah Enterprises Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1037 Maunakea St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Honolulu\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96817-5130\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 13, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS 736539\u003C\u002Fp>\u003Cp>Dear Mr. Au:\u003C\u002Fp>\u003Cp>On June 24, June 30, and July 1, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of BO WAH ENTERPRISES INC, 1037 Maunakea St, Honolulu, HI 96817-5130. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response, dated July 13, 2026, in which you stated your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong> develop your FSVP, requested HACCP and \u003Cstrong>(b)(4)\u003C\u002Fstrong> certificates from your foreign suppliers, and plans to send a firm member\u002Femployee to \u003Cstrong>(b)(4)\u003C\u002Fstrong> training. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Huai Shan (Chinese Yam), imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Golden Mushroom, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sesame Paste, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Golden Mushroom, imported from \u003Cstrong>(b)(4) \u003C\u002Fstrong>located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\u003C\u002Fp>\u003Cp>During our inspection close-out you provided the following documents:\u003C\u002Fp>\u003Cul>\u003Cli>HACCP plan containing a hazard analysis, a third-party audit report, and certificate from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>A Certificate of Analysis (COA) and a HACCP certificate from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; this document identified the US Importer as \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You stated you obtained these from your import liaisons. However, it is not clear how these documents would apply to your FSVP program, and you did not explain how they would apply to your FSVP program.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 934 Broadway, Suite 101, Tacoma, WA 98402; or via email to wcid@fda.hhs.gov, Attention: Sandra K. Wangen, Compliance Officer. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 736539 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDanny Y.W. Au\n\nRecipient Title\n\nPresident\n\nBo Wah Enterprises Inc\n\n1037 Maunakea St\n\nHonolulu, HI 96817-5130\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nAugust 13, 2026\nWARNING LETTER\nRe: CMS 736539\nDear Mr. Au:\nOn June 24, June 30, and July 1, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of BO WAH ENTERPRISES INC, 1037 Maunakea St, Honolulu, HI 96817-5130. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response, dated July 13, 2026, in which you stated your firm (b)(4) develop your FSVP, requested HACCP and (b)(4) certificates from your foreign suppliers, and plans to send a firm member\u002Femployee to (b)(4) training. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\n(b)(4) Huai Shan (Chinese Yam), imported from (b)(4) located in (b)(4)\n(b)(4) Golden Mushroom, imported from (b)(4) located in (b)(4)\n(b)(4) Sesame Paste, imported from (b)(4) located in (b)(4)\nFor thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to (b)(4) Golden Mushroom, imported from (b)(4) located in (b)(4) were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\nDuring our inspection close-out you provided the following documents:\nHACCP plan containing a hazard analysis, a third-party audit report, and certificate from your foreign supplier (b)(4) located in (b)(4)\nA Certificate of Analysis (COA) and a HACCP certificate from your foreign supplier (b)(4) located in (b)(4); this document identified the US Importer as (b)(4)\nYou stated you obtained these from your import liaisons. However, it is not clear how these documents would apply to your FSVP program, and you did not explain how they would apply to your FSVP program.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 934 Broadway, Suite 101, Tacoma, WA 98402; or via email to wcid@fda.hhs.gov, Attention: Sandra K. Wangen, Compliance Officer. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 736539 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","Bo Wah Enterprises Inc","bo-wah-enterprises-inc-736539-08132026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbo-wah-enterprises-inc-736539-08132026","2026-11-10T01:02:16.121874+00:00","2026-09-29","736539","Danny Y.W. Au","2026-10-14T12:34:32.17+00:00","Via Express Delivery","2026-08-13",{"id":76,"raw":77,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":49,"closeout_date":19,"issuing_office":36,"recipient_name":91,"body_fetched_at":92,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},2728,[78,79,80,36,81,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambi-enterprises-llc-628367-04132022\">AMBI Enterprises LLC \u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Lennarz \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>AMBI Enterprises LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10411 Motor City Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethesda\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20817-1008\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:consumercare@ambi.com\"> consumercare@ambi.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Lennarz:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of drug products to bleach and\u002For lighten the skin. AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product labels and labeling from your website https:\u002F\u002Fambi.com, where products are available for purchase, that provide evidence of the intended use(s) (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN\u003Cbr>\n“Fades dark spots for even, natural skin tone . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Bleaching Agent . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that effectively fades dark spots and skin discolorations to help restore your natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . \u003Cstrong>Hydroquinone\u003C\u002Fstrong> . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream OILY Skin” product label]\u003C\u002Fp>\n\n\u003Cp>“AMBI® Fade Cream Oily Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . \u003Cstrong>Hydroquinone-\u003C\u002Fstrong> a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-oily-skin]\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream NORMAL SKIN\u003Cbr>\n“Fade Cream . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Bleaching Agent . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or uneven pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that visibly fades dark spots and skin discolorations for an even, natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . \u003Cstrong>Hydroquinone\u003C\u002Fstrong> . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream NORMAL SKIN” product label]\u003C\u002Fp>\n\n\u003Cp>“AMBI® Fade Cream Normal Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . \u003Cstrong>Hydroquinone-\u003C\u002Fstrong> a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-normal-skin]\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are skin bleaching drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are deemed to be new drugs under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN. Accordingly, these skin bleaching drug products are unapproved new drugs and their introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020, to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid Lennarz\n\nAMBI Enterprises LLC\n\n10411 Motor City Drive\n\nBethesda, MD 20817-1008\n\nUnited States\n\nconsumercare@ambi.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Mr. Lennarz:\n\nThis letter concerns your firm’s distribution of drug products to bleach and\u002For lighten the skin. AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nAMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\n\nExamples of the claims observed on your product labels and labeling from your website https:\u002F\u002Fambi.com, where products are available for purchase, that provide evidence of the intended use(s) (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\n\nAMBI® SKINCARE Fade Cream OILY SKIN\n\n“Fades dark spots for even, natural skin tone . . . Drug Facts . . . Hydroquinone 2% . . . Purpose . . . Skin Bleaching Agent . . . Uses . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that effectively fades dark spots and skin discolorations to help restore your natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . Hydroquinone . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream OILY Skin” product label]\n\n“AMBI® Fade Cream Oily Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . Hydroquinone- a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-oily-skin]\n\nAMBI® SKINCARE Fade Cream NORMAL SKIN\n\n“Fade Cream . . . Drug Facts . . . Hydroquinone 2% . . . Purpose . . . Skin Bleaching Agent . . . Uses . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or uneven pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that visibly fades dark spots and skin discolorations for an even, natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . Hydroquinone . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream NORMAL SKIN” product label]\n\n“AMBI® Fade Cream Normal Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . Hydroquinone- a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-normal-skin]\n\nAMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are skin bleaching drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are deemed to be new drugs under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN. Accordingly, these skin bleaching drug products are unapproved new drugs and their introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\n\nIntroduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________________________\n\n1 On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020, to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","AMBI Enterprises LLC","ambi-enterprises-llc-628367-04132022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambi-enterprises-llc-628367-04132022","2026-10-26T08:07:54.399692+00:00","2022-04-19","628367","David Lennarz","2026-08-20T01:59:07.789+00:00","2022-04-13",{"id":95,"raw":96,"subject":61,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":105,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":26,"closeout_date":19,"issuing_office":100,"recipient_name":110,"body_fetched_at":111,"delivery_method":112,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},2428,[97,98,99,100,61,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-25T04:00:00Z\">07\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbacocas-enterprises-inc-633756-07252022\">Bacocas Enterprises Inc.\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ricardo (nmi) Cervantes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bacocas Enterprises Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2680 S. Bonnie Pl.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vernon\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90058-4312\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 25, 2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 633756\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Cervantes:\u003C\u002Fp>\n\n\u003Cp>On April 8, 2022, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Bacocas Enterprises, Inc. located at 2680 S. Bonnie Pl., Vernon, CA 90058-4312. We also conducted an inspection on June 16, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on April 8, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food that you import, including each of the following food products imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Watermelon\u003C\u002Fli>\n\t\u003Cli>Spaghetti squash\u003C\u002Fli>\n\t\u003Cli>Kabocha squash\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>You import watermelons, which are “covered produce” as defined in 21 CFR 112.3. Your FSVP must demonstrate that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. § 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via email at debbie.giang@fda.hhs.gov. Please reference CMS #633756 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRicardo (nmi) Cervantes\n\nRecipient Title\n\nOwner\n\nBacocas Enterprises Inc.\n\n2680 S. Bonnie Pl.\n\nVernon, CA 90058-4312\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nJuly 25, 2022\n\nRe: CMS # 633756\n\nDear Mr. Cervantes:\n\nOn April 8, 2022, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Bacocas Enterprises, Inc. located at 2680 S. Bonnie Pl., Vernon, CA 90058-4312. We also conducted an inspection on June 16, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on April 8, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food that you import, including each of the following food products imported from (b)(4) located in (b)(4):\n\nWatermelon\n\nSpaghetti squash\n\nKabocha squash\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nAdditionally, we offer the following comment:\n\nYou import watermelons, which are “covered produce” as defined in 21 CFR 112.3. Your FSVP must demonstrate that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. § 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via email at debbie.giang@fda.hhs.gov. Please reference CMS #633756 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Bacocas Enterprises Inc.","bacocas-enterprises-inc-633756-07252022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbacocas-enterprises-inc-633756-07252022","2026-10-26T08:08:00.298603+00:00","2022-09-20","633756","Ricardo (nmi) Cervantes","2026-08-20T01:33:03.881+00:00","VIA UNITED PARCEL SERVICE","2022-07-25",{"id":115,"raw":116,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":86,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":19,"issuing_office":120,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":128,"medical_device_id":19,"response_letter_date":19},2860,[117,118,119,120,121,13,13,13],"\u003Ctime datetime=\"2022-02-17T20:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-17T05:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flecig-enterprises-inc-624574-02172022\">Lecig Enterprises Inc\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Elias\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lecig Enterprises Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>810 West Collin Raye Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>De Queen\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>71832\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:me@lecig.com\"> me@lecig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 17, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Elias:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that LeCig Enterprises, Inc manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States LeCig Cinnamon Roll 36mg 30ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003586, on September 9, 2020. However, FDA issued a negative action for STN PM0003586 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 85 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003586 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200418, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMichael Elias\n\nRecipient Title\n\nOwner\n\nLecig Enterprises Inc\n\n810 West Collin Raye Drive\n\nDe Queen, AR 71832\n\nUnited States\n\nme@lecig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 17, 2022\n\nWARNING LETTER\n\nDear Mr. Elias:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that LeCig Enterprises, Inc manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States LeCig Cinnamon Roll 36mg 30ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003586, on September 9, 2020. However, FDA issued a negative action for STN PM0003586 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 85 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003586 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200418, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Lecig Enterprises Inc","lecig-enterprises-inc-624574-02172022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flecig-enterprises-inc-624574-02172022","2026-10-26T08:09:13.233972+00:00","2022-02-17","624574","Tobacco","Michael Elias","2026-08-20T02:10:13.7+00:00","VIA UPS and Electronic Mail",{"id":135,"raw":136,"subject":141,"body_html":143,"body_text":144,"firm_name":145,"letter_id":146,"created_at":147,"fei_number":19,"letter_url":148,"updated_at":149,"action_type":22,"case_status":46,"posted_date":150,"marcs_cms_no":151,"product_type":26,"closeout_date":152,"issuing_office":140,"recipient_name":153,"body_fetched_at":154,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":155,"medical_device_id":19,"response_letter_date":19},1389,[137,138,139,140,141,13,142,13],"\u003Ctime datetime=\"2024-07-09T13:20:00Z\">07\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-03T04:00:00Z\">06\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchoos-enterprises-ltd-683922-06032024\">Choo&#039;s Enterprises Ltd\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchoos-enterprises-ltd-683922-05272025\">\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edwin Cho\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Choo's Enterprises Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Jordan's Complex\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eagle Hall\u003C\u002Fspan>, \u003Cspan>Saint Michael\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Barbados\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference # 683922\u003C\u002Fp>\n\n\u003Cp>June 3, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Cho,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your low acid and acidified foods facility, Choo's Enterprises Ltd, located at Jordan's Complex, Saint Michael, Barbados on March 4 through 6, 2024. The inspection revealed serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, a Form FDA 483 (FDA 483), Inspectional Observations, was issued listing the deviations found at your facility. We acknowledge receipt of your response received via email on April 4, 2024, which included a written response, a training record, and photographs. However, our evaluation of the documentation revealed that the response was not adequate, as further described in this letter.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of acidified food products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the federal regulations relating to the processing of acidified foods. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration and filing of process information, and the mandatory requirements in 21 CFR 114. Regulations specific to the processing of acidified food products are described in 21 CFR Part 108 and 21 CFR 114. As outlined in these regulations, a commercial processor that does not adhere to all of the mandatory requirements of 21 CFR 108.25 and 21 CFR 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344).\u003C\u002Fp>\n\n\u003Cp>As stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You can find the Act and acidified foods regulations through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. As a commercial processor of acidified foods, you must, not later than 60 days after registration and prior to the packing of a new product, provide the FDA information as to the scheduled processes, as required by 21 CFR 108.25(c)(2). For acidified foods, this information must include conditions for heat processing and control of pH, salt, sugar, and preservative level, and source and date of the establishment of the process, for each acidified food in each container size. Specifically, you do not have a scheduled process on file with FDA for products you have identified as acidified products, which include, but are not limited to, Windmill Baxter's Road Seasoning, Windmill Classic Mauby Syrup, Sweet &amp; Tasty Mauby Syrup, Sugar Free Mauby Syrup, Ginger Beer Syrup, and Sugar Free Ginger Beer. Further, the scheduled process must be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods, as required by 21 CFR 114.83.\u003C\u002Fp>\n\n\u003Cp>Scheduled process information for acidified foods must be submitted on Form FDA 2541e a (Food Process Filing for Acidified Method). More information on registration and filing can be found in the publication \"Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format'' available at: http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\u003C\u002Fp>\n\n\u003Cp>Your response stated “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You further stated that you are consulting with a process authority. However, your response did not address whether you plan to file a scheduled process for your acidified food products. You will be unable to offer acidified food products for entry into the United States without scheduled processes on file with FDA.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the acidified foods regulations (21 CFR Parts 108 and 114) and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the acidified foods regulations (21 CFR Parts 108 and 114) is Import Alert #99-37, “Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes.” This alert can be found on FDA's web site at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fimportalert_1132.html.\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm’s operators of processing and packaging systems are not under the operating supervisions of a person who has attended and satisfactorily completed a school approved by the FDA for pH controls and critical factors in acidification. Although your response indicated that you will be having your Food Safety and Quality Assurance Officer take an online acidified foods manufacturing school, you did not provide any information on whether they have registered for the course or when they plan to take the course.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation and information that will assist us in evaluating your corrections such as evidence of submission of scheduled processes and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the acidified foods regulations. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the U.S. Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, Maryland 20740 U.S.A. If you have any questions regarding this letter, you may contact Ms. Phillips via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS # 683922 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nEdwin Cho\n\nRecipient Title\n\nCEO\n\nChoo's Enterprises Ltd\n\nJordan's Complex\n\nEagle Hall, Saint Michael\n\nBarbados\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nReference # 683922\n\nJune 3, 2024\n\nDear Mr. Cho,\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your low acid and acidified foods facility, Choo's Enterprises Ltd, located at Jordan's Complex, Saint Michael, Barbados on March 4 through 6, 2024. The inspection revealed serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, a Form FDA 483 (FDA 483), Inspectional Observations, was issued listing the deviations found at your facility. We acknowledge receipt of your response received via email on April 4, 2024, which included a written response, a training record, and photographs. However, our evaluation of the documentation revealed that the response was not adequate, as further described in this letter.\n\nAs a manufacturer of acidified food products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the federal regulations relating to the processing of acidified foods. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration and filing of process information, and the mandatory requirements in 21 CFR 114. Regulations specific to the processing of acidified food products are described in 21 CFR Part 108 and 21 CFR 114. As outlined in these regulations, a commercial processor that does not adhere to all of the mandatory requirements of 21 CFR 108.25 and 21 CFR 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344).\n\nAs stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You can find the Act and acidified foods regulations through links in FDA’s home page at www.fda.gov.\n\nYour significant deviations are as follows:\n\n1. As a commercial processor of acidified foods, you must, not later than 60 days after registration and prior to the packing of a new product, provide the FDA information as to the scheduled processes, as required by 21 CFR 108.25(c)(2). For acidified foods, this information must include conditions for heat processing and control of pH, salt, sugar, and preservative level, and source and date of the establishment of the process, for each acidified food in each container size. Specifically, you do not have a scheduled process on file with FDA for products you have identified as acidified products, which include, but are not limited to, Windmill Baxter's Road Seasoning, Windmill Classic Mauby Syrup, Sweet & Tasty Mauby Syrup, Sugar Free Mauby Syrup, Ginger Beer Syrup, and Sugar Free Ginger Beer. Further, the scheduled process must be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods, as required by 21 CFR 114.83.\n\nScheduled process information for acidified foods must be submitted on Form FDA 2541e a (Food Process Filing for Acidified Method). More information on registration and filing can be found in the publication \"Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format'' available at: http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\n\nYour response stated “(b)(4).” You further stated that you are consulting with a process authority. However, your response did not address whether you plan to file a scheduled process for your acidified food products. You will be unable to offer acidified food products for entry into the United States without scheduled processes on file with FDA.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the acidified foods regulations (21 CFR Parts 108 and 114) and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the acidified foods regulations (21 CFR Parts 108 and 114) is Import Alert #99-37, “Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes.” This alert can be found on FDA's web site at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fimportalert_1132.html.\n\nAdditionally, we offer the following comment:\n\nYour firm’s operators of processing and packaging systems are not under the operating supervisions of a person who has attended and satisfactorily completed a school approved by the FDA for pH controls and critical factors in acidification. Although your response indicated that you will be having your Food Safety and Quality Assurance Officer take an online acidified foods manufacturing school, you did not provide any information on whether they have registered for the course or when they plan to take the course.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation and information that will assist us in evaluating your corrections such as evidence of submission of scheduled processes and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the acidified foods regulations. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the U.S. Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, Maryland 20740 U.S.A. If you have any questions regarding this letter, you may contact Ms. Phillips via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS # 683922 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","Choo's Enterprises Ltd","choos-enterprises-ltd-683922-06032024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchoos-enterprises-ltd-683922-06032024","2026-10-26T08:08:14.967321+00:00","2024-07-09","683922","2025-06-03","Edwin Cho","2026-08-19T23:59:05.755+00:00","2024-06-03",{"id":157,"raw":158,"subject":165,"body_html":166,"body_text":167,"firm_name":168,"letter_id":169,"created_at":170,"fei_number":19,"letter_url":171,"updated_at":172,"action_type":22,"case_status":46,"posted_date":173,"marcs_cms_no":174,"product_type":175,"closeout_date":176,"issuing_office":162,"recipient_name":177,"body_fetched_at":178,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":179,"medical_device_id":19,"response_letter_date":19},3140,[159,160,161,162,163,13,164,13],"\u003Ctime datetime=\"2021-09-14T13:20:00Z\">09\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-20T04:00:00Z\">07\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrilliant-enterprises-llc-609523-07202021\">Brilliant Enterprises LLC\u003C\u002Fa>","Office of Human and Animal Food Operations Division- East 6","Unapproved New Drugs\u002FMisbranded ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrilliant-enterprises-llc-609523-12062021\">\u003Ctime datetime=\"2021-12-14T05:00:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail \n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Adam and Angela Schultz\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Brilliant Enterprises LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>621 Main Street, Unit 182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaylord\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49735\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@levelupmushrooms.com\"> support@levelupmushrooms.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division- East 6\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY 21- HAFE6 WL- 03\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 20, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Adam and Angela Schultz:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Flevelupmushrooms.comin June and July 2021 and has determined that you take orders there for the products Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX. We have also reviewed your social media websites atwww.instagram.com\u002Flevelupmushrooms and https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms, which direct consumers to your website https:\u002F\u002Flevelupmushrooms.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims observed on your websites that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Lion’s Mane\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Lion’s Mane of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “Protects Against Ulcers in the Stomach: Goodbye Pain”\u003Cbr>\n• “Relieves Depression and Anxiety: We All Need Relief”\u003Cbr>\n• “[R]elieves depression and anxiety…”\u003C\u002Fp>\n\n\u003Cp>On the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Lion’s Mane Scientific Studies”:\u003Cbr>\n• “Lion’s Mane May Be Effective in Combating Dementia\u002FAlzheimer’s Disease”\u003Cbr>\n• “Lion’s Mane Has Shown In Studies That It Could Reduce Anxiety And Depression”\u003Cbr>\n• “Animal Testing Shows Lion’s Mane Helps Control Diabetes Symptoms By Keeping Blood Sugar Low”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>BoomChaga\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for BoomChaga of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “Lowers Cholesterol: Live Longer”\u003Cbr>\n• “BoomChaga is 100% Chaga Mushroom. …More importantly, this mushroom is absolutely LOADED in antioxidants which are known cancer fighters.”\u003Cbr>\n• “Chaga contains more antioxidants . . . Antioxidants are those things that you always hear about but don’t know what they do. What they do is … because they repair DNA and ward off cancer. . . . it also improves health by showing its ability to fight inflammation and help with irritable bowel syndrom in other studies.”\u003Cbr>\n• “Data has shown that Chaga could help ward off the following health problems: Diabetes, lrratable Bowel Syndrome, and viral infections such as Herpes.”\u003C\u002Fp>\n\n\u003Cp>On the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Chaga (BOOMCHAGA!) Scientific Studies”:\u003Cbr>\n• “Potential For Fighting Cancer Due To The Extremely High Level of Anti-oxidants In Chaga”\u003Cbr>\n• “Anti-diabetic Effects”\u003Cbr>\n• “Help For Inflammatory Bowel Disease (irritable bowel)”\u003Cbr>\n• “Anti-viral Effects (herpes simplex)”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CordaCex\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for CordaCex of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “CORDACEX BENEFITS…reduces inflammation, shows cancer fighting properties...”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>LVL:MAX\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for LVL:MAX of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “Our product has helped 100's of people with anxiety and other mental problems...”\u003C\u002Fp>\n\n\u003Cp>On your social media website www.instagram.com\u002Flevelupmushrooms:\u003Cbr>\n• “…Feeling a little down and depressed?… Did you know we can help with all that and more with just some awesome mushrooms?... #LevelUpMushrooms . . . #DepressionAndAnxiety #BeatDepression #BeatAnxiety. . .” [From a June 25, 2020 post that includes an image of your LVL:MAX product]\u003C\u002Fp>\n\n\u003Cp>On your social media website https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms:\u003Cbr>\n• “LVL:MAX . . . Protects Against Ulcers in the Stomach: Goodbye Pain… Relieves Depression and Anxiety… Lowers Cholesterol: Live Longer…Lower Inflammation…” [From a Nov 12, 2019 post]\u003C\u002Fp>\n\n\u003Cp>Your Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)].With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Lauren Sexton, Compliance Officer, 300 River Place, Suite 5900, Detroit, MI 48207 or by email to Lauren.Sexton@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision- East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAdam and Angela Schultz\n\nBrilliant Enterprises LLC\n\n621 Main Street, Unit 182\n\nGaylord, MI 49735\n\nUnited States\n\nsupport@levelupmushrooms.com\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division- East 6\n\nUnited States\n\nWARNING LETTER\n\nFY 21- HAFE6 WL- 03\n\nJuly 20, 2021\n\nDear Adam and Angela Schultz:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Flevelupmushrooms.comin June and July 2021 and has determined that you take orders there for the products Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX. We have also reviewed your social media websites atwww.instagram.com\u002Flevelupmushrooms and https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms, which direct consumers to your website https:\u002F\u002Flevelupmushrooms.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the claims observed on your websites that provide evidence that your products are intended for use as drugs include:\n\nLion’s Mane\n\nOn the product webpage for Lion’s Mane of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “Protects Against Ulcers in the Stomach: Goodbye Pain”\n\n• “Relieves Depression and Anxiety: We All Need Relief”\n\n• “[R]elieves depression and anxiety…”\n\nOn the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Lion’s Mane Scientific Studies”:\n\n• “Lion’s Mane May Be Effective in Combating Dementia\u002FAlzheimer’s Disease”\n\n• “Lion’s Mane Has Shown In Studies That It Could Reduce Anxiety And Depression”\n\n• “Animal Testing Shows Lion’s Mane Helps Control Diabetes Symptoms By Keeping Blood Sugar Low”\n\nBoomChaga\n\nOn the product webpage for BoomChaga of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “Lowers Cholesterol: Live Longer”\n\n• “BoomChaga is 100% Chaga Mushroom. …More importantly, this mushroom is absolutely LOADED in antioxidants which are known cancer fighters.”\n\n• “Chaga contains more antioxidants . . . Antioxidants are those things that you always hear about but don’t know what they do. What they do is … because they repair DNA and ward off cancer. . . . it also improves health by showing its ability to fight inflammation and help with irritable bowel syndrom in other studies.”\n\n• “Data has shown that Chaga could help ward off the following health problems: Diabetes, lrratable Bowel Syndrome, and viral infections such as Herpes.”\n\nOn the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Chaga (BOOMCHAGA!) Scientific Studies”:\n\n• “Potential For Fighting Cancer Due To The Extremely High Level of Anti-oxidants In Chaga”\n\n• “Anti-diabetic Effects”\n\n• “Help For Inflammatory Bowel Disease (irritable bowel)”\n\n• “Anti-viral Effects (herpes simplex)”\n\nCordaCex\n\nOn the product webpage for CordaCex of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “CORDACEX BENEFITS…reduces inflammation, shows cancer fighting properties...”\n\nLVL:MAX\n\nOn the product webpage for LVL:MAX of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “Our product has helped 100's of people with anxiety and other mental problems...”\n\nOn your social media website www.instagram.com\u002Flevelupmushrooms:\n\n• “…Feeling a little down and depressed?… Did you know we can help with all that and more with just some awesome mushrooms?... #LevelUpMushrooms . . . #DepressionAndAnxiety #BeatDepression #BeatAnxiety. . .” [From a June 25, 2020 post that includes an image of your LVL:MAX product]\n\nOn your social media website https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms:\n\n• “LVL:MAX . . . Protects Against Ulcers in the Stomach: Goodbye Pain… Relieves Depression and Anxiety… Lowers Cholesterol: Live Longer…Lower Inflammation…” [From a Nov 12, 2019 post]\n\nYour Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)].With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Lauren Sexton, Compliance Officer, 300 River Place, Suite 5900, Detroit, MI 48207 or by email to Lauren.Sexton@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nDivision- East 6","Brilliant Enterprises LLC","brilliant-enterprises-llc-609523-07202021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrilliant-enterprises-llc-609523-07202021","2026-10-26T08:08:09.100562+00:00","2021-09-14","609523","DrugsFood & Beverages","2021-12-14","Adam and Angela Schultz","2026-08-20T02:36:00.42+00:00","2021-07-20",{"id":181,"raw":182,"subject":187,"body_html":188,"body_text":189,"firm_name":190,"letter_id":191,"created_at":170,"fei_number":19,"letter_url":192,"updated_at":193,"action_type":22,"case_status":23,"posted_date":194,"marcs_cms_no":195,"product_type":49,"closeout_date":19,"issuing_office":186,"recipient_name":196,"body_fetched_at":197,"delivery_method":198,"recipient_title":19,"reference_number":19,"action_taken_date":199,"medical_device_id":19,"response_letter_date":19},3131,[183,184,185,186,187,13,13,13],"\u003Ctime datetime=\"2021-09-28T13:20:00Z\">09\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-06T04:00:00Z\">08\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-poppy-enterprises-inc-614126-08062021\">Blue Poppy Enterprises Inc\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Young Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Blue Poppy Enterprises Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4804 SE 69th Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Portland\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 6, 2021\u003C\u002Fp>\n\n\u003Cp>CMS 614126\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Li:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.peoplesherbs.com in June and August 2021, and has determined that you take orders there for the products Modified Perilla &amp; Mentha, Empowered Cordyceps, Empowered Reishi, AllerEase, Empowered Eleuthro, Sui Bian Guo, Chinese Herbal Shampoo, Jade Dew Ointment, Stop Pain Tincture, Dr. Bob’s Medicated Oil, Cut &amp; Sore Ointment, E-C-Z Ointment, Organic Cactus Seed (Prickly Pear) Oil Antioxidant Facial Serum, Skin Soothing Ointment, and Dragon’s Blood Liniment. We have also reviewed your website at Internet address www.bluepoppy.com, which you link to your website www.peopleherbs.com, your Amazon Marketplace webpage, and three of your social media websites. Your social media sites https:\u002F\u002Fwww.facebook.com\u002F PeoplesHerbs\u002F and https:\u002F\u002Ftwitter.com\u002Fpeoples herbs?lang=en direct consumers to your product website, www.peoplesherbs.com, where products can be purchased. Additionally, your Instagram feed is accessible from your main page on your website www.peoplesherbs.com.\u003C\u002Fp>\n\n\u003Cp>The claims on your websites and social media pages establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Modified Perilla &amp; Mentha\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Modified Perilla &amp; Mentha at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CHINESE MEDICAL DIAGNOSIS: Gu chong (gu worms) leading to xie xie (diarrhea), xia li (dysentery), xiao fu tong (lower abdominal pain)…”\u003C\u002Fli>\n\t\u003Cli>“PATTERN DISCRIMINATION: Spleen qi vacuity with stomach and intestinal dampness and heat complicated by liver depression, stomach fluid dryness, and heart qi and blood vacuity”\u003C\u002Fli>\n\t\u003Cli>“THERAPUTIC[sic] ACTIONS:…combats gu and kills worms.”\u003C\u002Fli>\n\t\u003Cli>“INDICATIONS: This formula is for spleen qi vacuity with stomach and intestinal dampness and heat complicated by liver depression, stomach fluid dryness, and heart qi and blood vacuity. In terms of disease indications, it treats gu parasites with abdominal distention, loose stools or diarrhea, and abdominal cramping. Patients with this scenario have usually been diagnosed as suffering from intestinal parasites, intestinal dysbiosis, candidiasis, leaky gut syndrome, food allergies, and\u002For hypoglycemia. They may have irritable bowel syndrome, Crohn’s disease, ME, or chronic allergic rhinitis\u002Fsinusitis.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the Modified Perilla &amp; Mentha webpage found at www.bluepoppy.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[W]idely applicable in cases of various types of digestive weakness that include a history of multiple parasitic infections.”\u003C\u002Fli>\n\t\u003Cli>“Consider in cases of spleen qi vacuity with intestinal damp heat complicated by liver depression, stomach dryness, heart qi and blood vacuity.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Empowered Cordyceps\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Empowered Cordyceps at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Cordyceps has significant health benefits including being one of the best substances an asthmatics can include in their diet; a well-regarded tonic to help with recovery from long-term or significant illnesses…”\u003C\u002Fli>\n\t\u003Cli>“Cordyceps is also regarded traditionally as a recovery tonic. In China it is often employed to help people recover from long-term or significant illnesses…It is thought to have a particularly strengthening effect on kidney and lung function.”\u003C\u002Fli>\n\t\u003Cli>“Sexual debility is an ever-increasing issue in modern life. One need only watch television to note the many drug ads for pills to elevate sexual performance. In the U.S. it is estimated that 5% of 40 year-old men and 15-25% of 65 year old men have erectile dysfunction. This is another area, along with its role on the training table of athletes, where demand is driving the overharvesting. The sex drive is so central to one’s sense of well-being that people will pay a king’s ransom for a product that holds out hope for remedying the loss of sexual vitality. And Chinese studies do seem to indicate there is some hope for help with Cordyceps, even when consumed in a modest dose.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your Amazon Marketplace product webpage.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Empowered Reishi\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Empowered Reishi at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Reishi…can help with…support role with various types of cancer…”\u003C\u002Fli>\n\t\u003Cli>“…[H]elp with blood sugar regulation.”\u003C\u002Fli>\n\t\u003Cli>“…Reishi is valued world-wide for its use in a wide range of conditions. Clinically, Reishi is useful for symptoms of blood…deficiency…”\u003C\u002Fli>\n\t\u003Cli>“…[B]eneficial action on blood sugar regulation.”\u003C\u002Fli>\n\t\u003Cli>“…[A]nti-hypertensive properties. Hepatic fibrosis is also shown to be inhibited by [herbs in Reishi].”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the Empowered Reishi webpage at www.bluepoppy.com, under the Detailed\u003Cbr>\nDescription:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Reishi is useful for patients with symptoms of blood…deficiency . . ..”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the Product Information Sheet, accessible to view from your Empowered Reishi product page, at www.bluepoppy.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Other compound in reishi are shown in research to have beneficial action on blood sugar regulation.”\u003C\u002Fli>\n\t\u003Cli>“…[A]nti-hypertensive properties. Hepatic fibrosis is also shown to be inhibited…”\u003C\u002Fli>\n\t\u003Cli>“…[S]upportive role with various types of cancer, demonstrates neuro-protective actions…and reduces anxiety.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your Amazon Marketplace product webpage. For example, at https:\u002F\u002Fwww.amazon.com\u002FEmpowered-Reishi-100-Capsules-Peoples\u002Fdp\u002FB08YH1WXN2\u002Fref=sr_1_1?dchild=1&amp;keywords=Empowered+Reishi&amp;qid=1627574049&amp;sr=8-1:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…Reishi is valued world-wide for its use in a wide range of conditions. Reishi is useful for those with symptoms of blood…deficiency…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>AllerEase\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for AllerEase at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[C]lear, runny nose and stuffed nose.”\u003C\u002Fli>\n\t\u003Cli>“CHINESE DISEASE DIAGNOSIS…\u003Cem>Bi liu ti\u003C\u002Fem> (runny nose), \u003Cem>pen ti\u003C\u002Fem> (sneezing), \u003Cem>bi se\u003C\u002Fem> (nasal congestion), \u003Cem>bi yang\u003C\u002Fem> (itchy nose), \u003Cem>mu yang\u003C\u002Fem> (itchy eyes)”\u003C\u002Fli>\n\t\u003Cli>“PATTERN DISCRIMINATION…insufficient spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\u003C\u002Fli>\n\t\u003Cli>“THERAPEUTIC ACTIONS…eliminates dampness and transforms phlegm, stops itching and opens the flow of the nasal orifices”\u003C\u002Fli>\n\t\u003Cli>“INDICATIONS…For acute episodes of allergic rhinitis characterized by clear, runny, itchy nose, itchy eyes, and sneezing…spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the Product Information Sheet, accessible from your AllerEase product page at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[C]lear, runny nose and stuffed nose.”\u003C\u002Fli>\n\t\u003Cli>“CHINESE DISEASE DIAGNOSIS \u003Cem>Bi liu ti\u003C\u002Fem> (runny nose), \u003Cem>pen ti\u003C\u002Fem> (sneezing), \u003Cem>bi se\u003C\u002Fem> (nasal congestion), \u003Cem>bi yang\u003C\u002Fem> (itchy nose), \u003Cem>mu yang\u003C\u002Fem> (itchy eyes)”\u003C\u002Fli>\n\t\u003Cli>“PATTERN DISCRIMINATION…insufficient spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\u003C\u002Fli>\n\t\u003Cli>“THERAPEUTIC ACTIONS…eliminates dampness and transforms phlegm, stops itching and opens the flow of the nasal orifices”\u003C\u002Fli>\n\t\u003Cli>“INDICATIONS The remedial treatment of acute episodes of allergic rhinitis characterized by clear, runny, itchy nose, itchy eyes, and sneezing…spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\u003C\u002Fli>\n\t\u003Cli>“FORMULATOR’S COMMENTS …not so likely to cause excessive dryness of the mucus membranes as does prolonged use of Western medical anticongestants.”\u003C\u002Fli>\n\t\u003Cli>“THE SIGNS AND SYMPTOMS OF WIND COLD ALLERGIC RHINITIS INCLUDE…Episodic or seasonal sneezing due to airborne allergens…Clear, watery runny nose…Itchy nose…Itchy eyes…Nasal congestion”\u003C\u002Fli>\n\t\u003Cli>“THE SIGNS AND SYMPTOMS OF SPLEEN VACUITY INCLUDE…An enlarged tongue with teeth-marks on its edges and white fur…A possible soggy pulse…Possible loose stools…”\u003C\u002Fli>\n\t\u003Cli>“In Chinese medicine, people who contract airborne allergies…mostly due to a chronically vacuous and weak spleen failing to engender the lungs…there may also be a kidney qi vacuity…obstruct the lungs’ diffusion and downbearing… tendency to phlegm dampness…whenever the lungs’ diffusion and downbearing of fluids is inhibited, this phlegm…becoming apparent as mucus.”\u003C\u002Fli>\n\t\u003Cli>“…[T]his formula…secure the lungs and specifically stop[s] runny nose…open the orifices and free the flow of the nose, thus relieving nasal con- gestion…stops itching…seeps dampness via urination and, therefore…eliminate dampness…helping fortify the spleen…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Empowered Eleuthro\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Empowered Eleuthro at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Chronic infections”\u003C\u002Fli>\n\t\u003Cli>“Declining eyesight”\u003C\u002Fli>\n\t\u003Cli>“Chronic inflammatory condition”\u003C\u002Fli>\n\t\u003Cli>“…[H]elp with…deficiency without creating unwanted side-effects…for given complaints…With Red Rice Yeast Plus for patients who have minor lipid problems.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog posting All About Eleuthro from www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[F]ormulated to help with…deficiency without creating unwanted sideeffects…”\u003C\u002Fli>\n\t\u003Cli>“…[T]hought to have a therapeutic focus on lungs, spleen, and kidneys. It can be of use in conditions of joint stiffness and pain…”\u003C\u002Fli>\n\t\u003Cli>“…[F]or those minor cholesterol problems”\u003C\u002Fli>\n\t\u003Cli>“Chronic infections”\u003C\u002Fli>\n\t\u003Cli>“Declining eyesight”\u003C\u002Fli>\n\t\u003Cli>“Chronic inflammatory conditions”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Sui Bian Guo\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Sui Bian Guo at your, www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[R]elieving constipation…”\u003C\u002Fli>\n\t\u003Cli>“Mulberry leaf powder…has the functions of resisting bacteria, removing toxicity…”\u003C\u002Fli>\n\t\u003Cli>“Mate tea…is a regulator of the heart, nerves and muscles that can prevent the deterioration of body function;…scavenging cholesterol...”\u003C\u002Fli>\n\t\u003Cli>“Dietary fiber…prevent[s] constipation and hemorrhoids...Dietary fiber can reduce…cholesterol absorption in the gut and promote the discharge of cholesterol and cholic acid, with an effect of reducing…blood fat, and cholesterol.”\u003C\u002Fli>\n\t\u003Cli>“Beta-Carotene…improving nyctalopia, human immunity…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your product webpage at www.bluepoppy.com; and your Twitter and Facebook webpages, which offer direct links to your www.peoplesherbs.com webpage. These include but are not limited to the following on your Twitter webpage:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[E]xcellent for relieving constipation…resisting bacteria…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>And the following on your Facebook webpage:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[E]xcellent for relieving constipation…resisting bacteria…”\u003C\u002Fli>\n\t\u003Cli>“…[P]opular remedy for constipation…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Chinese Herbal Shampoo\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for the product Chinese Herbal Shampoo, at www.peoplesherbs.com and www.bluepoppy.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[Q]uickens the blood in the scalp.”\u003C\u002Fli>\n\t\u003Cli>“…[A]nti-inflammatory, bacteriostatic, and bacteriocidal… also helps in tissue regeneration.”\u003C\u002Fli>\n\t\u003Cli>“…[E]liminate dandruff…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your Amazon Marketplace product webpage.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dragon’s Blood Liniment\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Dragon’s Blood Liniment at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“This liniment is for blood stasis due to traumatic injury when there is pronounced pain and ecchymosis.”\u003C\u002Fli>\n\t\u003Cli>“Quickens the blood and dispels stasis…disperses swelling, and stops pain.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Similar claims are found on your Amazon Marketplace product webpage as well as your product’s web page at www.bluepoppy.com.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Jade Dew Ointment\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Jade Dew Ointment at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Clears heat and cools the blood, disperses swelling, and resolves toxins.”\u003C\u002Fli>\n\t\u003Cli>“Recommended for cold sores (herpes simplex).”\u003C\u002Fli>\n\t\u003Cli>“Use: Apply externally at the first sign of a cold sore…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the Jade Dew Ointment webpage at www.bluepoppy.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[R]ecommend it for the treatment of herpes simplex in … ‘The Chinese Medical Treatment of Viral Diseases’”\u003C\u002Fli>\n\t\u003Cli>“Clears heat and cools the blood, disperses swelling and resolves toxins”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your Amazon Marketplace product webpage.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Stop Pain Tincture\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Stop Pain Tincture at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[Q]uickens the blood, and stops pain.”\u003C\u002Fli>\n\t\u003Cli>“Appy externally to the site of pain.”\u003C\u002Fli>\n\t\u003Cli>“Formula Rationale Hong Hua (Flos Carthami) is a blood-quickening medicinal. It quickens the blood and transforms stasis. Hong Hua is a commonly used medicinal…for both traumatological and impediment pain conditions…Gan Song Xiang…is [a]…medicinal…stops pain…arouse the spleen and clear away turbidity (when taken internally). In terms of its pain-stopping ability, this medicinal…has pronounced sedative and anodyne effects.”\u003C\u002Fli>\n\t\u003Cli>“…[Alcohol] quickens the blood. Alcohol also potentizes the medicinal effects of other ingredients…is both a medium and an active ingredient in its own right.”\u003C\u002Fli>\n\t\u003Cli>“…[E]very type of pain is due to some sort of non-free flow…distention, intermittent or movable pain, and gripping or cramping pain…intense, localized, sharp, stabbing pain…accompanied by swelling…or inflammation…main principles in Chinese medicine for treating any kind of pain…and quicken the blood…. pain automatically disappears. It is axiomatic in Chinese medicine that, “If there’s free flow; there is no pain.”\u003C\u002Fli>\n\t\u003Cli>“…[D]iverse types of pain as tennis elbow, lumbar vertebral hyperplasia, lumbar disk protrusion, osteoarthritis arthritis, rheumatoid arthritis, dysmenorrhea, and stomach and duodenal ulcers…relief of pain…pain caused by traumatological injury…periarthritis…lumbar hyperplasia…dysmenorrhea…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Dr. Bobs Medicated Oil\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Dr. Bob’s Medicated Oil at www.peoplesherbs.com.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Medicated Oil”\u003C\u002Fli>\n\t\u003Cli>“…[P]roven healing power for all sorts of complaints…”\u003C\u002Fli>\n\t\u003Cli>“…[Q]uickens the blood, disperses inflammation and stops pain and itching”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Similar claims are found on your Amazon Marketplace product webpage as well as your product’s web page at www.bluepoppy.com.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cut &amp; Sore Ointment\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Cut &amp; Sore Ointment at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“…[Q]uicken the blood and stop pain…engenders the flesh…clears heat and alleviates pain.”\u003C\u002Fli>\n\t\u003Cli>“Clears heat and resolves toxins, moves the blood and stops pain, engenders flesh and eliminates putridity”\u003C\u002Fli>\n\t\u003Cli>“Apply to open cuts or sores one or more times a day.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your website www.bluepoppy.com.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E-C-Z Ointment\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for E-C-Z Ointment at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“For…eczema. Blue Poppy’s E-C-Z ointment clears heat and eliminates dampness, dispels wind, and stops itching.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Organic Cactus Seed (Prickly Pear) Oil Antioxidant Facial Serum\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Organic Cactus Seed (Prickly Pear) Oil Antioxidant Facial Serum at www.peoplesherbs.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Regenerates the skin and slows down its aging process, thereby preventing wrinkles”\u003C\u002Fli>\n\t\u003Cli>“Like argan oil itself, it can also be used directly for treating…scar tissue and fissures.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Skin Soothing Ointment\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage for Skin Soothing Ointment at www.peoplesherbs.com and posts March 26, 2021, on your https:\u002F\u002Fwww.facebook.com\u002F PeoplesHerbs\u002F and https:\u002F\u002Fwww.instagram.com\u002Fpeoples_herbs\u002F social media sites:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Blue Poppy’s Skin Soothing ointment is for topical application to burns and scalds. It clears heat and dries dampness, cools the blood and resolves toxins, quickens the blood and stops pain, transforms stasis and eliminates the putrid, closes sores and engenders flesh.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, similar claims are present on your Instagram feed, accessible to view from your, www.peoplesherbs.com, webpage, as well as your Instagram, Twitter and Facebook webpages, as found at, https:\u002F\u002Fwww.instagram.com\u002Fpeoples_herbs\u002F, https:\u002F\u002Ftwitter.com\u002Fpeoplesh erbs?lang=en, and https:\u002F\u002Fwww.facebook.com\u002F PeoplesHerbs\u002F, respectively which offer direct links to your, www.peoplesherbs.com, website where products can be purchased.\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), § 355(a)]. FDA approves a new drug based on scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Modified Perilla &amp; Mentha, Empowered Cordyceps, Empowered Reishi, Sui Bian Guo, and Stop Pain Tincture are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Modified Perilla &amp; Mentha, Empowered Cordyceps, Empowered Reishi, Sui Bian Guo, and Stop Pain Tincture products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the Food and Drug Administration, Attention: Amy R. Glynn, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Glynn at 425-302-0411.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nYoung Li\n\nRecipient Title\n\nOwner\n\nBlue Poppy Enterprises Inc\n\n4804 SE 69th Avenue\n\nPortland, OR 97206\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nAugust 6, 2021\n\nCMS 614126\n\nWARNING LETTER\n\nDear Mr. Li:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.peoplesherbs.com in June and August 2021, and has determined that you take orders there for the products Modified Perilla & Mentha, Empowered Cordyceps, Empowered Reishi, AllerEase, Empowered Eleuthro, Sui Bian Guo, Chinese Herbal Shampoo, Jade Dew Ointment, Stop Pain Tincture, Dr. Bob’s Medicated Oil, Cut & Sore Ointment, E-C-Z Ointment, Organic Cactus Seed (Prickly Pear) Oil Antioxidant Facial Serum, Skin Soothing Ointment, and Dragon’s Blood Liniment. We have also reviewed your website at Internet address www.bluepoppy.com, which you link to your website www.peopleherbs.com, your Amazon Marketplace webpage, and three of your social media websites. Your social media sites https:\u002F\u002Fwww.facebook.com\u002F PeoplesHerbs\u002F and https:\u002F\u002Ftwitter.com\u002Fpeoples herbs?lang=en direct consumers to your product website, www.peoplesherbs.com, where products can be purchased. Additionally, your Instagram feed is accessible from your main page on your website www.peoplesherbs.com.\n\nThe claims on your websites and social media pages establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nModified Perilla & Mentha\n\nOn your webpage for Modified Perilla & Mentha at www.peoplesherbs.com:\n\n“CHINESE MEDICAL DIAGNOSIS: Gu chong (gu worms) leading to xie xie (diarrhea), xia li (dysentery), xiao fu tong (lower abdominal pain)…”\n\n“PATTERN DISCRIMINATION: Spleen qi vacuity with stomach and intestinal dampness and heat complicated by liver depression, stomach fluid dryness, and heart qi and blood vacuity”\n\n“THERAPUTIC[sic] ACTIONS:…combats gu and kills worms.”\n\n“INDICATIONS: This formula is for spleen qi vacuity with stomach and intestinal dampness and heat complicated by liver depression, stomach fluid dryness, and heart qi and blood vacuity. In terms of disease indications, it treats gu parasites with abdominal distention, loose stools or diarrhea, and abdominal cramping. Patients with this scenario have usually been diagnosed as suffering from intestinal parasites, intestinal dysbiosis, candidiasis, leaky gut syndrome, food allergies, and\u002For hypoglycemia. They may have irritable bowel syndrome, Crohn’s disease, ME, or chronic allergic rhinitis\u002Fsinusitis.”\n\nOn the Modified Perilla & Mentha webpage found at www.bluepoppy.com:\n\n“…[W]idely applicable in cases of various types of digestive weakness that include a history of multiple parasitic infections.”\n\n“Consider in cases of spleen qi vacuity with intestinal damp heat complicated by liver depression, stomach dryness, heart qi and blood vacuity.”\n\nEmpowered Cordyceps\n\nOn your webpage for Empowered Cordyceps at www.peoplesherbs.com:\n\n“Cordyceps has significant health benefits including being one of the best substances an asthmatics can include in their diet; a well-regarded tonic to help with recovery from long-term or significant illnesses…”\n\n“Cordyceps is also regarded traditionally as a recovery tonic. In China it is often employed to help people recover from long-term or significant illnesses…It is thought to have a particularly strengthening effect on kidney and lung function.”\n\n“Sexual debility is an ever-increasing issue in modern life. One need only watch television to note the many drug ads for pills to elevate sexual performance. In the U.S. it is estimated that 5% of 40 year-old men and 15-25% of 65 year old men have erectile dysfunction. This is another area, along with its role on the training table of athletes, where demand is driving the overharvesting. The sex drive is so central to one’s sense of well-being that people will pay a king’s ransom for a product that holds out hope for remedying the loss of sexual vitality. And Chinese studies do seem to indicate there is some hope for help with Cordyceps, even when consumed in a modest dose.”\n\nAdditionally, similar claims are present on your Amazon Marketplace product webpage.\n\nEmpowered Reishi\n\nOn your webpage for Empowered Reishi at www.peoplesherbs.com:\n\n“Reishi…can help with…support role with various types of cancer…”\n\n“…[H]elp with blood sugar regulation.”\n\n“…Reishi is valued world-wide for its use in a wide range of conditions. Clinically, Reishi is useful for symptoms of blood…deficiency…”\n\n“…[B]eneficial action on blood sugar regulation.”\n\n“…[A]nti-hypertensive properties. Hepatic fibrosis is also shown to be inhibited by [herbs in Reishi].”\n\nOn the Empowered Reishi webpage at www.bluepoppy.com, under the Detailed\n\nDescription:\n\n“Reishi is useful for patients with symptoms of blood…deficiency . . ..”\n\nOn the Product Information Sheet, accessible to view from your Empowered Reishi product page, at www.bluepoppy.com:\n\n“Other compound in reishi are shown in research to have beneficial action on blood sugar regulation.”\n\n“…[A]nti-hypertensive properties. Hepatic fibrosis is also shown to be inhibited…”\n\n“…[S]upportive role with various types of cancer, demonstrates neuro-protective actions…and reduces anxiety.”\n\nAdditionally, similar claims are present on your Amazon Marketplace product webpage. For example, at https:\u002F\u002Fwww.amazon.com\u002FEmpowered-Reishi-100-Capsules-Peoples\u002Fdp\u002FB08YH1WXN2\u002Fref=sr_1_1?dchild=1&keywords=Empowered+Reishi&qid=1627574049&sr=8-1:\n\n“…Reishi is valued world-wide for its use in a wide range of conditions. Reishi is useful for those with symptoms of blood…deficiency…”\n\nAllerEase\n\nOn your webpage for AllerEase at www.peoplesherbs.com:\n\n“…[C]lear, runny nose and stuffed nose.”\n\n“CHINESE DISEASE DIAGNOSIS…Bi liu ti (runny nose), pen ti (sneezing), bi se (nasal congestion), bi yang (itchy nose), mu yang (itchy eyes)”\n\n“PATTERN DISCRIMINATION…insufficient spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\n\n“THERAPEUTIC ACTIONS…eliminates dampness and transforms phlegm, stops itching and opens the flow of the nasal orifices”\n\n“INDICATIONS…For acute episodes of allergic rhinitis characterized by clear, runny, itchy nose, itchy eyes, and sneezing…spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\n\nOn the Product Information Sheet, accessible from your AllerEase product page at www.peoplesherbs.com:\n\n“…[C]lear, runny nose and stuffed nose.”\n\n“CHINESE DISEASE DIAGNOSIS Bi liu ti (runny nose), pen ti (sneezing), bi se (nasal congestion), bi yang (itchy nose), mu yang (itchy eyes)”\n\n“PATTERN DISCRIMINATION…insufficient spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\n\n“THERAPEUTIC ACTIONS…eliminates dampness and transforms phlegm, stops itching and opens the flow of the nasal orifices”\n\n“INDICATIONS The remedial treatment of acute episodes of allergic rhinitis characterized by clear, runny, itchy nose, itchy eyes, and sneezing…spleen (and possibly kidney) vacuity with deep-lying phlegm rheum.”\n\n“FORMULATOR’S COMMENTS …not so likely to cause excessive dryness of the mucus membranes as does prolonged use of Western medical anticongestants.”\n\n“THE SIGNS AND SYMPTOMS OF WIND COLD ALLERGIC RHINITIS INCLUDE…Episodic or seasonal sneezing due to airborne allergens…Clear, watery runny nose…Itchy nose…Itchy eyes…Nasal congestion”\n\n“THE SIGNS AND SYMPTOMS OF SPLEEN VACUITY INCLUDE…An enlarged tongue with teeth-marks on its edges and white fur…A possible soggy pulse…Possible loose stools…”\n\n“In Chinese medicine, people who contract airborne allergies…mostly due to a chronically vacuous and weak spleen failing to engender the lungs…there may also be a kidney qi vacuity…obstruct the lungs’ diffusion and downbearing… tendency to phlegm dampness…whenever the lungs’ diffusion and downbearing of fluids is inhibited, this phlegm…becoming apparent as mucus.”\n\n“…[T]his formula…secure the lungs and specifically stop[s] runny nose…open the orifices and free the flow of the nose, thus relieving nasal con- gestion…stops itching…seeps dampness via urination and, therefore…eliminate dampness…helping fortify the spleen…”\n\nEmpowered Eleuthro\n\nOn your webpage for Empowered Eleuthro at www.peoplesherbs.com:\n\n“Chronic infections”\n\n“Declining eyesight”\n\n“Chronic inflammatory condition”\n\n“…[H]elp with…deficiency without creating unwanted side-effects…for given complaints…With Red Rice Yeast Plus for patients who have minor lipid problems.”\n\nOn your blog posting All About Eleuthro from www.peoplesherbs.com:\n\n“…[F]ormulated to help with…deficiency without creating unwanted sideeffects…”\n\n“…[T]hought to have a therapeutic focus on lungs, spleen, and kidneys. It can be of use in conditions of joint stiffness and pain…”\n\n“…[F]or those minor cholesterol problems”\n\n“Chronic infections”\n\n“Declining eyesight”\n\n“Chronic inflammatory conditions”\n\nSui Bian Guo\n\nOn your webpage for Sui Bian Guo at your, www.peoplesherbs.com:\n\n“…[R]elieving constipation…”\n\n“Mulberry leaf powder…has the functions of resisting bacteria, removing toxicity…”\n\n“Mate tea…is a regulator of the heart, nerves and muscles that can prevent the deterioration of body function;…scavenging cholesterol...”\n\n“Dietary fiber…prevent[s] constipation and hemorrhoids...Dietary fiber can reduce…cholesterol absorption in the gut and promote the discharge of cholesterol and cholic acid, with an effect of reducing…blood fat, and cholesterol.”\n\n“Beta-Carotene…improving nyctalopia, human immunity…”\n\nAdditionally, similar claims are present on your product webpage at www.bluepoppy.com; and your Twitter and Facebook webpages, which offer direct links to your www.peoplesherbs.com webpage. These include but are not limited to the following on your Twitter webpage:\n\n“…[E]xcellent for relieving constipation…resisting bacteria…”\n\nAnd the following on your Facebook webpage:\n\n“…[E]xcellent for relieving constipation…resisting bacteria…”\n\n“…[P]opular remedy for constipation…”\n\nChinese Herbal Shampoo\n\nOn your webpage for the product Chinese Herbal Shampoo, at www.peoplesherbs.com and www.bluepoppy.com:\n\n“…[Q]uickens the blood in the scalp.”\n\n“…[A]nti-inflammatory, bacteriostatic, and bacteriocidal… also helps in tissue regeneration.”\n\n“…[E]liminate dandruff…”\n\nAdditionally, similar claims are present on your Amazon Marketplace product webpage.\n\nDragon’s Blood Liniment\n\nOn your webpage for Dragon’s Blood Liniment at www.peoplesherbs.com:\n\n“This liniment is for blood stasis due to traumatic injury when there is pronounced pain and ecchymosis.”\n\n“Quickens the blood and dispels stasis…disperses swelling, and stops pain.”\n\nSimilar claims are found on your Amazon Marketplace product webpage as well as your product’s web page at www.bluepoppy.com.\n\nJade Dew Ointment\n\nOn your webpage for Jade Dew Ointment at www.peoplesherbs.com:\n\n“Clears heat and cools the blood, disperses swelling, and resolves toxins.”\n\n“Recommended for cold sores (herpes simplex).”\n\n“Use: Apply externally at the first sign of a cold sore…”\n\nOn the Jade Dew Ointment webpage at www.bluepoppy.com:\n\n“[R]ecommend it for the treatment of herpes simplex in … ‘The Chinese Medical Treatment of Viral Diseases’”\n\n“Clears heat and cools the blood, disperses swelling and resolves toxins”\n\nAdditionally, similar claims are present on your Amazon Marketplace product webpage.\n\nStop Pain Tincture\n\nOn your webpage for Stop Pain Tincture at www.peoplesherbs.com:\n\n“…[Q]uickens the blood, and stops pain.”\n\n“Appy externally to the site of pain.”\n\n“Formula Rationale Hong Hua (Flos Carthami) is a blood-quickening medicinal. It quickens the blood and transforms stasis. Hong Hua is a commonly used medicinal…for both traumatological and impediment pain conditions…Gan Song Xiang…is [a]…medicinal…stops pain…arouse the spleen and clear away turbidity (when taken internally). In terms of its pain-stopping ability, this medicinal…has pronounced sedative and anodyne effects.”\n\n“…[Alcohol] quickens the blood. Alcohol also potentizes the medicinal effects of other ingredients…is both a medium and an active ingredient in its own right.”\n\n“…[E]very type of pain is due to some sort of non-free flow…distention, intermittent or movable pain, and gripping or cramping pain…intense, localized, sharp, stabbing pain…accompanied by swelling…or inflammation…main principles in Chinese medicine for treating any kind of pain…and quicken the blood…. pain automatically disappears. It is axiomatic in Chinese medicine that, “If there’s free flow; there is no pain.”\n\n“…[D]iverse types of pain as tennis elbow, lumbar vertebral hyperplasia, lumbar disk protrusion, osteoarthritis arthritis, rheumatoid arthritis, dysmenorrhea, and stomach and duodenal ulcers…relief of pain…pain caused by traumatological injury…periarthritis…lumbar hyperplasia…dysmenorrhea…”\n\nDr. Bobs Medicated Oil\n\nOn your webpage for Dr. Bob’s Medicated Oil at www.peoplesherbs.com.\n\n“Medicated Oil”\n\n“…[P]roven healing power for all sorts of complaints…”\n\n“…[Q]uickens the blood, disperses inflammation and stops pain and itching”\n\nSimilar claims are found on your Amazon Marketplace product webpage as well as your product’s web page at www.bluepoppy.com.\n\nCut & Sore Ointment\n\nOn your webpage for Cut & Sore Ointment at www.peoplesherbs.com:\n\n“…[Q]uicken the blood and stop pain…engenders the flesh…clears heat and alleviates pain.”\n\n“Clears heat and resolves toxins, moves the blood and stops pain, engenders flesh and eliminates putridity”\n\n“Apply to open cuts or sores one or more times a day.”\n\nAdditionally, similar claims are present on your website www.bluepoppy.com.\n\nE-C-Z Ointment\n\nOn your webpage for E-C-Z Ointment at www.peoplesherbs.com:\n\n“For…eczema. Blue Poppy’s E-C-Z ointment clears heat and eliminates dampness, dispels wind, and stops itching.”\n\nOrganic Cactus Seed (Prickly Pear) Oil Antioxidant Facial Serum\n\nOn your webpage for Organic Cactus Seed (Prickly Pear) Oil Antioxidant Facial Serum at www.peoplesherbs.com:\n\n“Regenerates the skin and slows down its aging process, thereby preventing wrinkles”\n\n“Like argan oil itself, it can also be used directly for treating…scar tissue and fissures.”\n\nSkin Soothing Ointment\n\nOn your webpage for Skin Soothing Ointment at www.peoplesherbs.com and posts March 26, 2021, on your https:\u002F\u002Fwww.facebook.com\u002F PeoplesHerbs\u002F and https:\u002F\u002Fwww.instagram.com\u002Fpeoples_herbs\u002F social media sites:\n\n“Blue Poppy’s Skin Soothing ointment is for topical application to burns and scalds. It clears heat and dries dampness, cools the blood and resolves toxins, quickens the blood and stops pain, transforms stasis and eliminates the putrid, closes sores and engenders flesh.”\n\nAdditionally, similar claims are present on your Instagram feed, accessible to view from your, www.peoplesherbs.com, webpage, as well as your Instagram, Twitter and Facebook webpages, as found at, https:\u002F\u002Fwww.instagram.com\u002Fpeoples_herbs\u002F, https:\u002F\u002Ftwitter.com\u002Fpeoplesh erbs?lang=en, and https:\u002F\u002Fwww.facebook.com\u002F PeoplesHerbs\u002F, respectively which offer direct links to your, www.peoplesherbs.com, website where products can be purchased.\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), § 355(a)]. FDA approves a new drug based on scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Modified Perilla & Mentha, Empowered Cordyceps, Empowered Reishi, Sui Bian Guo, and Stop Pain Tincture are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Modified Perilla & Mentha, Empowered Cordyceps, Empowered Reishi, Sui Bian Guo, and Stop Pain Tincture products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to the Food and Drug Administration, Attention: Amy R. Glynn, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Glynn at 425-302-0411.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","Blue Poppy Enterprises Inc","blue-poppy-enterprises-inc-614126-08062021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-poppy-enterprises-inc-614126-08062021","2026-10-26T08:08:06.779716+00:00","2021-09-28","614126","Young Li","2026-08-20T02:35:23.946+00:00","Overnight Delivery","2021-08-06",{"id":201,"raw":202,"subject":207,"body_html":208,"body_text":209,"firm_name":210,"letter_id":211,"created_at":147,"fei_number":19,"letter_url":212,"updated_at":213,"action_type":22,"case_status":23,"posted_date":214,"marcs_cms_no":215,"product_type":49,"closeout_date":19,"issuing_office":206,"recipient_name":216,"body_fetched_at":217,"delivery_method":218,"recipient_title":19,"reference_number":19,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},1349,[203,204,205,206,207,13,13,13],"\u003Ctime datetime=\"2024-07-23T13:20:00Z\">07\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-05T04:00:00Z\">06\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyahon-enterprise-co-ltd-675592-06052024\">Yahon Enterprise Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hsu Ke Fu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Factory Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Yahon Enterprise Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>An Chu Hamlet, Tay Lac Village\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bac Son Commune\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Trang Bom District\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>76000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vietnam\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jacky@yaho.com.vn\"> jacky@yaho.com.vn\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-40\u003C\u002Fp>\n\n\u003Cp>June 5, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hsu Ke Fu:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Yahon Enterprise Co. Ltd., FEI 3017151342 at An Chu Hamlet, Tay Lac Village, Bac Son Commune, Trang Bom District, from December 15 to 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response to our Form FDA 483, received January 11, 2024, in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You released over-the-counter (OTC)&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;drug products without adequate quality control testing, including but not limited to the identity and strength of each active ingredient. For example, identity and potency testing was not performed for the active ingredient in your ethyl alcohol antiseptic wipes distributed in the U.S. market.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use, including both chemical and microbiological specifications. Because you lacked testing of each batch of your drug products, you do not know whether they conform to finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>In your response, you provide your test method and procedure used to perform identity and potency testing for the active ingredient in your drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response lacks sufficient justification for the testing you perform, which does not establish comparability to United States Pharmacopeia (USP) standards.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing on each lot of ethyl alcohol and benzylkonium chloride used to manufacture your OTC drug products. Because you did not perform adequate identity testing on each shipment of each lot, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to testing ethyl alcohol and benzylkonium chloride ingredients by a third party \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response lacks specificity regarding your plans to test each lot of each shipment of incoming components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Products Contain Ethanol (Methanol Risk)\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm assigned a three-year expiry period to ethyl alcohol antiseptic wipes without scientific rationale to support the labeled expiry. At the time of inspection, you lacked stability data to substantiate the three-year expiry period and there was no assurance that your drug products will remain acceptable throughout their labeled expiry period without an ongoing stability program.\u003C\u002Fp>\n\n\u003Cp>In your response, you explain that your three-year expiry date is based on accelerated stability and “quality confirmation” after inventory has been stored for 3 years.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You fail to provide data to demonstrate that chemical and microbiological properties of your drug products will remain within specification throughout their labeled expiry period.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Stability indicating methods\u003Cbr>\no Stability studies for each drug product in its marketed container-closure system before distribution\u003Cbr>\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\no Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>\no All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) lacked adequate control over your OTC drug manufacturing operations and failed to ensure that you had adequate procedures. For example, your QU failed to ensure:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate validation of manufacturing processes for ethyl alcohol antiseptic wipes (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate cleaning validation for equipment used in the manufacture of ethyl alcohol antiseptic wipes (21 CFR 211.67(b)).\u003C\u002Fli>\n\t\u003Cli>Adequate storage and retention of CGMP records (21 CFR 211.180(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate collection and storage of reserve samples (21 CFR 211.170(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you acknowledge these deficiencies and provide your plan for implementing procedures and training.\u003C\u002Fp>\n\n\u003Cp>Your response is insufficient because you fail to provide documentation confirming the implementation and adherence to these processes and procedures.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\no A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Drugs with higher toxicities\u003Cbr>\no Drugs with higher drug potencies\u003Cbr>\no Drugs of lower solubility in their cleaning solvents\u003Cbr>\no Drugs with characteristics that make them difficult to clean\u003Cbr>\no Swabbing locations for areas that are most difficult to clean\u003Cbr>\no Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, assessment of your reserve sample system. This assessment should include, but not be limited to, your procedure(s) to ensure reserve samples are appropriately identified, stored, and maintained. Your reserve sample program should also include provisions for verifying sample integrity and adherence to retention time requirements.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Yahon Enterprise Co. Ltd., An Chu Hamlet, Tay Lac Village, Bac Son Commune, Trang Bom District, Vietnam, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017151342 and ATTN: Joseph Lambert, Pharm.D.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Hsu Ke Fu\n\nRecipient Title\n\nFactory Manager\n\nYahon Enterprise Co., Ltd.\n\nAn Chu Hamlet, Tay Lac Village\n\nBac Son Commune\n\nTrang Bom District\n\n76000\n\nVietnam\n\njacky@yaho.com.vn\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-40\n\nJune 5, 2024\n\nDear Mr. Hsu Ke Fu:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Yahon Enterprise Co. Ltd., FEI 3017151342 at An Chu Hamlet, Tay Lac Village, Bac Son Commune, Trang Bom District, from December 15 to 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your response to our Form FDA 483, received January 11, 2024, in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYou released over-the-counter (OTC) (b)(4) drug products without adequate quality control testing, including but not limited to the identity and strength of each active ingredient. For example, identity and potency testing was not performed for the active ingredient in your ethyl alcohol antiseptic wipes distributed in the U.S. market.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use, including both chemical and microbiological specifications. Because you lacked testing of each batch of your drug products, you do not know whether they conform to finished product specifications and are suitable for release to consumers.\n\nIn your response, you provide your test method and procedure used to perform identity and potency testing for the active ingredient in your drug products.\n\nYour response is inadequate. Your response lacks sufficient justification for the testing you perform, which does not establish comparability to United States Pharmacopeia (USP) standards.\n\nIn response to this letter, provide a list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision, and the associated written procedures.\n\n2. Your firm failed to test samples of each component for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(2)).\n\nYou failed to perform adequate identity testing on each lot of ethyl alcohol and benzylkonium chloride used to manufacture your OTC drug products. Because you did not perform adequate identity testing on each shipment of each lot, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nIn your response, you commit to testing ethyl alcohol and benzylkonium chloride ingredients by a third party (b)(4).\n\nYour response is inadequate. Your response lacks specificity regarding your plans to test each lot of each shipment of incoming components.\n\nProducts Contain Ethanol (Methanol Risk)\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n3. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\n\nYour firm assigned a three-year expiry period to ethyl alcohol antiseptic wipes without scientific rationale to support the labeled expiry. At the time of inspection, you lacked stability data to substantiate the three-year expiry period and there was no assurance that your drug products will remain acceptable throughout their labeled expiry period without an ongoing stability program.\n\nIn your response, you explain that your three-year expiry date is based on accelerated stability and “quality confirmation” after inventory has been stored for 3 years.\n\nYour response is inadequate. You fail to provide data to demonstrate that chemical and microbiological properties of your drug products will remain within specification throughout their labeled expiry period.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\no All procedures that describe these and other elements of your remediated stability program.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) lacked adequate control over your OTC drug manufacturing operations and failed to ensure that you had adequate procedures. For example, your QU failed to ensure:\n\nAdequate validation of manufacturing processes for ethyl alcohol antiseptic wipes (21 CFR 211.100(a)).\n\nAdequate cleaning validation for equipment used in the manufacture of ethyl alcohol antiseptic wipes (21 CFR 211.67(b)).\n\nAdequate storage and retention of CGMP records (21 CFR 211.180(a)).\n\nAdequate collection and storage of reserve samples (21 CFR 211.170(a)).\n\nIn your response, you acknowledge these deficiencies and provide your plan for implementing procedures and training.\n\nYour response is insufficient because you fail to provide documentation confirming the implementation and adherence to these processes and procedures.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM070337.pdf.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\n\nA timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nA comprehensive, assessment of your reserve sample system. This assessment should include, but not be limited to, your procedure(s) to ensure reserve samples are appropriately identified, stored, and maintained. Your reserve sample program should also include provisions for verifying sample integrity and adherence to retention time requirements.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Yahon Enterprise Co. Ltd., An Chu Hamlet, Tay Lac Village, Bac Son Commune, Trang Bom District, Vietnam, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017151342 and ATTN: Joseph Lambert, Pharm.D.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Yahon Enterprise Co., Ltd.","yahon-enterprise-co-ltd-675592-06052024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyahon-enterprise-co-ltd-675592-06052024","2026-10-26T08:10:35.688403+00:00","2024-07-23","675592","Mr. Hsu Ke Fu","2026-08-19T23:57:14.797+00:00","VIA EMAIL WITH READ RECEIPT","2024-06-05",{"id":221,"raw":222,"subject":12,"body_html":226,"body_text":227,"firm_name":228,"letter_id":229,"created_at":18,"fei_number":19,"letter_url":230,"updated_at":231,"action_type":22,"case_status":23,"posted_date":232,"marcs_cms_no":233,"product_type":234,"closeout_date":19,"issuing_office":11,"recipient_name":235,"body_fetched_at":236,"delivery_method":237,"recipient_title":19,"reference_number":19,"action_taken_date":238,"medical_device_id":19,"response_letter_date":19},566,[223,224,225,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-17T04:00:00Z\">07\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalentine-enterprises-inc-705119-07172025\">Valentine Enterprises, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alan W. Smith\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Valentine Enterprises, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1291 Progress Center Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lawrenceville\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30043-4801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:awsmith@veiusa.com\"> awsmith@veiusa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 705119\u003C\u002Fp>\u003Cp>Dear Mr. Smith:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1291 Progress Center Ave., Lawrenceville, GA 30043-4801 from October 8 – 24, 2024. Based on inspectional findings and review of the product documents collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on October 24, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 7, and December 5, 2024, and January 31, February 28, March 31, 2025, May 30, and June 30, 2025, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from October 8 through October 24, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement product, Vibrant Health Green Vibrance (“VH Green Vibrance”), manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. Your firm failed to, for each dietary supplement that you manufacture, establish product specifications for the identity, purity, strength, composition and limits on contamination of the finished batch of the dietary supplement as required in 21 CFR 111.70(e).\u003C\u002Fp>\u003Cp>Specifically, your document, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for your product VH Green Vibrance, does not establish an identity specification that includes a test method that will adequately identify the finished product. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” sheet purports to use organoleptic attributes (taste, texture, aroma and color), with a specification that states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for identity testing. However, this does not provide sufficient detail for your firm to be able to confirm the identity of a multi-ingredient finished product in powder form, and it does not ensure that you can distinguish one product from any other mix of powdered substances. Additionally:\u003C\u002Fp>\u003Cp>- Only eighteen of the dietary ingredients in VH Green Vibrance are listed to be tested on a rotating basis, which is not adequate to establish identity for each batch of the dietary supplement, and there is no acceptance criteria written on the specification form.\u003C\u002Fp>\u003Cp>Your responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated finished product specifications for VH Green Vibrance. They include methods for some of the ingredients, however, the frequency of first lot\u002Fannually or rotating is not supported by a scientific rationale as to how this confirms the identity specifications of every lot. Additionally, some of the test methods are from private labs or internal, so we are unable to evaluate if they are adequate for the intended target.\u003C\u002Fp>\u003Cp>Additionally, for VH Green Vibrance, the label lists probiotic bacteria ingredients and respective quantities, but you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We understand you are in discussions with the client about taking corrective action on this issue. We will evaluate the adequacy of your corrective action at the next inspection.\u003C\u002Fp>\u003Cp>We note that in addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\u003Cp>2. You failed to verify that the laboratory examination and testing methodologies are appropriate for their intended use, as required by 21 CFR 111.320(a).\u003C\u002Fp>\u003Cp>Specifically, you rely on a third-party laboratory to conduct your pathogen testing for finished products. Your third-party laboratory said they did not determine the suitability of the following methods for testing VH Green Vibrance:\u003C\u002Fp>\u003Cul>\u003Cli>BAM chapter 12 for testing for presence of \u003Cem>S. aureus\u003C\u002Fem>;\u003C\u002Fli>\u003Cli>AOAC 991.14 for testing for presence of \u003Cem>E. coli\u003C\u002Fem>;\u003C\u002Fli>\u003Cli>AOAC-RI 121501 for testing for the presence of \u003Cem>Salmonella\u003C\u002Fem>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25, include updated finished product microbial testing specifications and you state you \u003Cstrong>(b)(4)\u003C\u002Fstrong> for pathogen testing for finished products. However, we are unable to evaluate the adequacy of your response because you did not provide supporting documentation demonstrating that you have verified that such tests are appropriate for their intended use in your products.\u003C\u002Fp>\u003Cp>3. Your firm failed to include complete information in your batch production records relating to the production and control of each batch, as required by 21 CFR 111.255(b) and in accordance with 21 CFR 111.260.\u003C\u002Fp>\u003Cp>Specifically, for VH Green Vibrance, your BPRs did not include:\u003C\u002Fp>\u003Cp>a. The date and time of maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained, as required by 21 CFR 111.260(c).\u003Cbr>b. The results of any testing or examination performed during the batch production, or a cross-reference to such results, as required by 21 CFR 111.260(h).\u003C\u002Fp>\u003Cp>Your responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated procedures and you reference updated MMRs which you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will evaluate the adequacy of your corrective actions at the next inspection.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the MuscleTech EuphoriQ Pre-Workout Watermelon Candy, VH Green Vibrance, Vibrant Health Joint Vibrance, and Premium Green Superfood Cytogreens products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements.\u003C\u002Fp>\u003Cp>1. The products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\u003C\u002Fp>\u003Cp>- For MuscleTech EuphoriQ Pre-Workout Watermelon Candy you declare the dietary ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” 10 mcg. Your MMRs’ “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” identifies the ingredient as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Your raw material specification 88-517 provided in your 2\u002F28\u002F25 response describes the ingredient as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” It appears that you add an extract of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but the label does not mention the extract.\u003C\u002Fp>\u003Cp>- For VH Green Vibrance – you declare as “\u003Cstrong>(b)(4)\u003C\u002Fstrong> natural flavor, which is not a common or usual name.\u003C\u002Fp>\u003Cp>- For Vibrant Health Joint Vibrance and Premium Green Superfood Cytogreens – the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> is not a common or usual name.\u003C\u002Fp>\u003Cp>2. The products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\u003C\u002Fp>\u003Cp>- For Vibrant Health Joint Vibrance - the product’s label declares serving size as 1 scoop. The directions state to take one to two (1 to 2) scoops.\u003C\u002Fp>\u003Cp>- For products 8 Greens Super Greens Powder and Premium Green Superfood Cytogreens - the serving size needs to be expressed using the term that is appropriate for the form of the supplement, such as “tablets,” “capsules,” “packets,” or “teaspoonfuls,” as required by 21 CFR 101.36(b)(1)(i). The appropriate term would be “1 Scoop (x g)” as stated in the directions for use.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>We also have the following comment:\u003C\u002Fp>\u003Cp>On the label of 8 Greens Super Greens Powder, you compare the amounts of vitamins and zinc to what is contained in fruits and vegetables. Please note all information on the product label must be truthful and not misleading.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Sara J. Dent Acosta, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #705119 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAlan W. Smith\n\nRecipient Title\n\nPresident\u002FCEO\n\nValentine Enterprises, Inc.\n\n1291 Progress Center Ave\n\nLawrenceville, GA 30043-4801\n\nUnited States\n\nawsmith@veiusa.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJuly 17, 2025\nWARNING LETTER\nCMS # 705119\nDear Mr. Smith:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1291 Progress Center Ave., Lawrenceville, GA 30043-4801 from October 8 – 24, 2024. Based on inspectional findings and review of the product documents collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on October 24, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 7, and December 5, 2024, and January 31, February 28, March 31, 2025, May 30, and June 30, 2025, and we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility from October 8 through October 24, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement product, Vibrant Health Green Vibrance (“VH Green Vibrance”), manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. Your firm failed to, for each dietary supplement that you manufacture, establish product specifications for the identity, purity, strength, composition and limits on contamination of the finished batch of the dietary supplement as required in 21 CFR 111.70(e).\nSpecifically, your document, “(b)(4)” for your product VH Green Vibrance, does not establish an identity specification that includes a test method that will adequately identify the finished product. Your “(b)(4)” sheet purports to use organoleptic attributes (taste, texture, aroma and color), with a specification that states “(b)(4)” for identity testing. However, this does not provide sufficient detail for your firm to be able to confirm the identity of a multi-ingredient finished product in powder form, and it does not ensure that you can distinguish one product from any other mix of powdered substances. Additionally:\n- Only eighteen of the dietary ingredients in VH Green Vibrance are listed to be tested on a rotating basis, which is not adequate to establish identity for each batch of the dietary supplement, and there is no acceptance criteria written on the specification form.\nYour responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated finished product specifications for VH Green Vibrance. They include methods for some of the ingredients, however, the frequency of first lot\u002Fannually or rotating is not supported by a scientific rationale as to how this confirms the identity specifications of every lot. Additionally, some of the test methods are from private labs or internal, so we are unable to evaluate if they are adequate for the intended target.\nAdditionally, for VH Green Vibrance, the label lists probiotic bacteria ingredients and respective quantities, but you state (b)(4). We understand you are in discussions with the client about taking corrective action on this issue. We will evaluate the adequacy of your corrective action at the next inspection.\nWe note that in addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n2. You failed to verify that the laboratory examination and testing methodologies are appropriate for their intended use, as required by 21 CFR 111.320(a).\nSpecifically, you rely on a third-party laboratory to conduct your pathogen testing for finished products. Your third-party laboratory said they did not determine the suitability of the following methods for testing VH Green Vibrance:\nBAM chapter 12 for testing for presence of S. aureus;\nAOAC 991.14 for testing for presence of E. coli;\nAOAC-RI 121501 for testing for the presence of Salmonella.\nYour responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25, include updated finished product microbial testing specifications and you state you (b)(4) for pathogen testing for finished products. However, we are unable to evaluate the adequacy of your response because you did not provide supporting documentation demonstrating that you have verified that such tests are appropriate for their intended use in your products.\n3. Your firm failed to include complete information in your batch production records relating to the production and control of each batch, as required by 21 CFR 111.255(b) and in accordance with 21 CFR 111.260.\nSpecifically, for VH Green Vibrance, your BPRs did not include:\na. The date and time of maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained, as required by 21 CFR 111.260(c).\nb. The results of any testing or examination performed during the batch production, or a cross-reference to such results, as required by 21 CFR 111.260(h).\nYour responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated procedures and you reference updated MMRs which you state (b)(4). We will evaluate the adequacy of your corrective actions at the next inspection.\nMisbranded Dietary Supplements\nIn addition, we reviewed your product labels collected during the inspection and have determined the MuscleTech EuphoriQ Pre-Workout Watermelon Candy, VH Green Vibrance, Vibrant Health Joint Vibrance, and Premium Green Superfood Cytogreens products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements.\n1. The products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\n- For MuscleTech EuphoriQ Pre-Workout Watermelon Candy you declare the dietary ingredient “(b)(4)” 10 mcg. Your MMRs’ “(b)(4)” identifies the ingredient as “(b)(4).” Your raw material specification 88-517 provided in your 2\u002F28\u002F25 response describes the ingredient as “(b)(4).” It appears that you add an extract of (b)(4), but the label does not mention the extract.\n- For VH Green Vibrance – you declare as “(b)(4) natural flavor, which is not a common or usual name.\n- For Vibrant Health Joint Vibrance and Premium Green Superfood Cytogreens – the “(b)(4) is not a common or usual name.\n2. The products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\n- For Vibrant Health Joint Vibrance - the product’s label declares serving size as 1 scoop. The directions state to take one to two (1 to 2) scoops.\n- For products 8 Greens Super Greens Powder and Premium Green Superfood Cytogreens - the serving size needs to be expressed using the term that is appropriate for the form of the supplement, such as “tablets,” “capsules,” “packets,” or “teaspoonfuls,” as required by 21 CFR 101.36(b)(1)(i). The appropriate term would be “1 Scoop (x g)” as stated in the directions for use.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nWe also have the following comment:\nOn the label of 8 Greens Super Greens Powder, you compare the amounts of vitamins and zinc to what is contained in fruits and vegetables. Please note all information on the product label must be truthful and not misleading.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Sara J. Dent Acosta, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #705119 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Valentine Enterprises, Inc.","valentine-enterprises-inc-705119-07172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalentine-enterprises-inc-705119-07172025","2026-10-26T08:10:19.11619+00:00","2025-09-30","705119","Dietary Supplements","Alan W. Smith","2026-08-19T16:16:58.748+00:00","Via Email","2025-07-17",{"id":240,"raw":241,"subject":245,"body_html":247,"body_text":248,"firm_name":249,"letter_id":250,"created_at":86,"fei_number":19,"letter_url":251,"updated_at":252,"action_type":22,"case_status":46,"posted_date":253,"marcs_cms_no":254,"product_type":175,"closeout_date":255,"issuing_office":140,"recipient_name":256,"body_fetched_at":257,"delivery_method":258,"recipient_title":19,"reference_number":19,"action_taken_date":259,"medical_device_id":19,"response_letter_date":19},2584,[242,243,244,140,245,13,246,13],"\u003Ctime datetime=\"2022-07-12T12:30:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-01T04:00:00Z\">07\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmks-enterprise-llc-624478-07012022\">MKS Enterprise, LLC\u003C\u002Fa>","Interstate Commerce\u002FFood\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmks-enterprise-llc-624478-09022022\">\u003Ctime datetime=\"2026-02-13T05:00:00Z\">02\u002F13\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Satish Bhatia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>MKS Enterprise, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>59 Paulison Ave. #13\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Passaic\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07055\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mks@wholesaleonline1.com\"> mks@wholesaleonline1.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sam77usa@gmail.com\"> sam77usa@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 624478\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bhatia,\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) obtained a sample of your product Dose Vital Royal Honey VIP Honey (Vital Honey) purchased directly from your website at www.wholesaleonline1.com. FDA also reviewed your website in June 2022. Based on our review of your website and laboratory analysis of your product, FDA has identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohibited Act under Section 301(ll)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA confirmed through laboratory analysis that a sample of your Vital Honey contains the undeclared active pharmaceutical ingredient tadalafil, which is a phosphodiesterase type-5 (PDE-5) inhibitor. Tadalafil is the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.\u003C\u002Fp>\n\n\u003Cp>Subject to a limited exception, it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(II)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&amp;C Act [21 U.S.C. 355] or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to tadalafil.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FDA is not aware of any evidence that would call into question its conclusion that section 301(ll) of the FD&amp;C Act prohibits the introduction into interstate commerce of any food to which tadalafil has been added.\u003C\u002Fp>\n\n\u003Cp>Your Vital Honey product is a food to which tadalafil has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(II) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at www.wholesaleonline1.com in June 2022 and determined you take orders there for the product Vital Honey. In addition to being a food of which the introduction or delivery for introduction into interstate commerce is prohibited under section 301(ll) of the FD&amp;C Act, this product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)], as established by the claims on your website, because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>- “Prevent arthritis and multiple sclerosis\u003Cbr>\n- Accelerating the healing and consolidation of fractured bones\u003Cbr>\n- Lower cholesterol\u003Cbr>\n- Alleviate cardiovascular ailments\u003Cbr>\n- Remedy liver disease, pancreatic, insomnia, fatigue, ulcers, and digestive and skin disorders\u003Cbr>\n- Reduce . . . anxiety states, insomnia and anorexia\u003Cbr>\n- Decreases prostate issues and illnesses in the man’s productive [sic] system.”\u003C\u002Fp>\n\n\u003Cp>Your Vital Honey is not generally recognized as safe and effective for the above-referenced uses and, therefore, the product is a “new drug” under section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product Vital Honey is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Vital Honey fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Additionally, we have the following comment:\u003C\u002Fp>\n\n\u003Cp>FDA has not conducted a complete review of your inventory. It is your responsibility under the FD&amp;C Act to ensure that products marketed by your firm do not contain undeclared ingredients and comply with all requirements of federal law. A full list of all tainted products discovered by FDA can be found at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder\u003C\u002Fa>. We recommend that you subscribe to our email service at&nbsp;\u003Ca href=\"https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew\">https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew\u003C\u002Fa> to receive regular notices about tainted products discovered by FDA.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply to the above violations should be directed to Kimberly Dutzek with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA approved Cialis™ (containing tadalafil as the active ingredient) as a new drug on November 21, 2003. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on available evidence, FDA has concluded that this is not the case for tadalafil.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSatish Bhatia\n\nMKS Enterprise, LLC\n\n59 Paulison Ave. #13\n\nPassaic, NJ 07055\n\nUnited States\n\nmks@wholesaleonline1.com\n\nsam77usa@gmail.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2022\n\nRE: 624478\n\nDear Mr. Bhatia,\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) obtained a sample of your product Dose Vital Royal Honey VIP Honey (Vital Honey) purchased directly from your website at www.wholesaleonline1.com. FDA also reviewed your website in June 2022. Based on our review of your website and laboratory analysis of your product, FDA has identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act).\n\nProhibited Act under Section 301(ll)\n\nFDA confirmed through laboratory analysis that a sample of your Vital Honey contains the undeclared active pharmaceutical ingredient tadalafil, which is a phosphodiesterase type-5 (PDE-5) inhibitor. Tadalafil is the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.\n\nSubject to a limited exception, it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(II)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&C Act [21 U.S.C. 355] or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to tadalafil.1 FDA is not aware of any evidence that would call into question its conclusion that section 301(ll) of the FD&C Act prohibits the introduction into interstate commerce of any food to which tadalafil has been added.\n\nYour Vital Honey product is a food to which tadalafil has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(II) of the FD&C Act.\n\nUnapproved New Drug\n\nFDA reviewed your website at www.wholesaleonline1.com in June 2022 and determined you take orders there for the product Vital Honey. In addition to being a food of which the introduction or delivery for introduction into interstate commerce is prohibited under section 301(ll) of the FD&C Act, this product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)], as established by the claims on your website, because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the FD&C Act.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\n- “Prevent arthritis and multiple sclerosis\n\n- Accelerating the healing and consolidation of fractured bones\n\n- Lower cholesterol\n\n- Alleviate cardiovascular ailments\n\n- Remedy liver disease, pancreatic, insomnia, fatigue, ulcers, and digestive and skin disorders\n\n- Reduce . . . anxiety states, insomnia and anorexia\n\n- Decreases prostate issues and illnesses in the man’s productive [sic] system.”\n\nYour Vital Honey is not generally recognized as safe and effective for the above-referenced uses and, therefore, the product is a “new drug” under section 201(p) of the FD&C Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nMisbranded Drug\n\nYour product Vital Honey is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Vital Honey fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nAdditionally, we have the following comment:\n\nFDA has not conducted a complete review of your inventory. It is your responsibility under the FD&C Act to ensure that products marketed by your firm do not contain undeclared ingredients and comply with all requirements of federal law. A full list of all tainted products discovered by FDA can be found at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder. We recommend that you subscribe to our email service at https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew to receive regular notices about tainted products discovered by FDA.\n\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply to the above violations should be directed to Kimberly Dutzek with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n___________________________\n\n1 FDA approved Cialis™ (containing tadalafil as the active ingredient) as a new drug on November 21, 2003. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on available evidence, FDA has concluded that this is not the case for tadalafil.","MKS Enterprise, LLC","mks-enterprise-llc-624478-07012022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmks-enterprise-llc-624478-07012022","2026-10-26T08:09:26.73709+00:00","2022-07-12","624478","2026-02-13","Satish Bhatia","2026-08-20T01:46:35.713+00:00","Via Overnight Delivery","2022-07-01",{"id":261,"raw":262,"subject":267,"body_html":268,"body_text":269,"firm_name":270,"letter_id":271,"created_at":147,"fei_number":19,"letter_url":272,"updated_at":273,"action_type":22,"case_status":23,"posted_date":274,"marcs_cms_no":275,"product_type":26,"closeout_date":19,"issuing_office":266,"recipient_name":276,"body_fetched_at":277,"delivery_method":278,"recipient_title":19,"reference_number":19,"action_taken_date":279,"medical_device_id":19,"response_letter_date":19},1417,[263,264,265,266,267,13,13,13],"\u003Ctime datetime=\"2024-06-18T13:20:00Z\">06\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-31T04:00:00Z\">05\u002F31\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchang-and-son-enterprises-inc-679517-05312024\">Chang and Son Enterprises, Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations East I","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u002FL. monocytogenes","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sidney Chang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chang and Son Enterprises, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 River Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Whately\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01093\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS # 679517\u003C\u002Fp>\n\n\u003Cp>5\u002F31\u002F2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chang,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) analyzed the environmental sample identified as sample 1245959, which consisted of 15 environmental swabs collected on December 20, 2023, from your sprouting operation at 301 River Road, Whately, MA, by the Commonwealth of Massachusetts Department of Agricultural Resources (MDAR) and determined that two of the fifteen swabs were positive for the presence of \u003Cem>Listeria monocytogenes (L. monocytogenes)\u003C\u002Fem>, a human pathogen. Based on FDA’s analysis of the environmental samples, we have determined that your mung bean and soybean sprouts are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. Additionally, based on evaluation of whole genome sequence (WGS) analysis, we determined that the isolates from sample 1245959 match each other and 10 other \u003Cem>L. monocytogenes\u003C\u002Fem> that were isolated from several product samples collected from April 23, 2023, through December 4, 2023.\u003C\u002Fp>\n\n\u003Cp>Based on this evaluation, we have determined that your mung bean sprouts are contaminated within the meaning of section 402(a)(1) of the Act, 21 U.S.C. § 342(a)(1), in that they contain a poisonous or deleterious substance which may render them injurious to health. You can find the Act and its implementing regulations through internet links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Pathogen Findings\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>L. monocytogenes\u003C\u002Fem> is a pathogenic bacterium that is widespread in the environment and may be introduced into a sprouting operation from raw materials, humans, or equipment. Without proper sanitation practices, it can proliferate in a sprouting operation where it may contaminate food. Consuming food contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening illness called listeriosis, a foodborne illness, which is a major public health concern due to the severity of the disease, its high case-fatality rate, long incubation time, and tendency to affect individuals with underlying conditions.\u003C\u002Fp>\n\n\u003Cp>FDA’s analysis of the environmental swabs collected by MDAR on December 20, 2023, confirmed that two of the fifteen swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. FDA also conducted WGS analysis on the environmental swabs taken by MDAR on December 20, 2023, and on the following samples of your mung bean sprouts:\u003C\u002Fp>\n\n\u003Cp>a. On April 24, 2023, New York State - Agriculture and Markets (NYSAGM) Division of Food Safety and Inspection collected a sample of mung bean sprouts identified as sample: FL No. 2339630013 \u002F Lab No. 23B04362. The sample was collected at a retail store located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, analyzed at the NYSAGM Division of Food Laboratory, and tested positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>b. On May 4, 2023, MDAR conducted an inspection of your sprout operation and collected a sample of mung bean sprouts identified as Event Code: 05042023\u002FLab #: 23EN2354. The sample was analyzed by Massachusetts State Public Health Laboratory, and the sample tested positive for the human pathogen \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>c. On December 4, 2023, Virginia Department of Agriculture and Consumer Services (VDACS) Food Safety Program collected a sample of mung bean sprouts identified as sample: E231200179 (VDACS ID 992007932). This sample collected as part of the FDA\u002FState Laboratory Flexible Funding Model (LFFM) sampling program and was collected at a retail supermarket located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Sample was analyzed by the VDACS Division of Consolidated Laboratory Services and tested positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>WGS analysis of bacterial human pathogens provides high-resolution data as it measures each DNA position in a bacterial genome, enabling direct links to be established between clinical isolates and food or environmental sources of bacterial contamination and illness. The WGS data can also be used to infer the evolutionary relationships (or phylogeny) of a given set of isolates. Six isolates identified in environmental sample 1245959 were found to match each other. These six isolates also matched ten isolates identified in the three product samples listed in the above descriptions, sample: FL No. 2339630013 \u002F Lab No. 23B04362, Event Code: 05042023\u002FLab #: 23EN2354, and E231200179 (VDACS ID 992007932). The high genetic similarity of the sixteen isolates and that they belong to the same strain suggests they likely came from the same source. The presence of \u003Cem>L. monocytogenes\u003C\u002Fem> in your operation is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your operation to prevent contamination of food.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you initiated a recall on May 9, 2023, in response to the positive \u003Cem>L. monocytogenes\u003C\u002Fem> findings from MDAR from samples of your product collected on May 4, 2023, and that you initiated a recall on December 15, 2023 in response to the positive \u003Cem>L. monocytogenes\u003C\u002Fem> findings from VDACS from samples of your product collected on December 4, 2023.\u003C\u002Fp>\n\n\u003Cp>In response to the above findings, FDA conducted an inspection of your sprouting operation located at 301 River Road., Whatley, Massachusetts, from January 10, 2024, through February 8, 2024, in accordance with Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption regulation (the Produce Safety Rule or PSR), Title 21, Code of Federal Regulations, Part 112 (21 CFR Part 112). We collected 91 environmental swabs, one of which, a sample from the bed of a truck outside your operation, yielded \u003Cem>L. monocytogenes\u003C\u002Fem>. At the close of the inspection, the FDA investigators issued your operation a Form FDA 483 (FDA-483), Inspectional Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your written response to the FDA-483, received February 20, 2024. You stated that you have taken various corrective actions, including holding an employee meeting on the importance of following various sanitary practices, appointing an employee to monitor employee practices, informing your laboratories of discrepancies, and establishing processes with your laboratory regarding reporting sample discrepancies, sample issues, sending alternate samples, and checking results. You also explained various standard operating procedures and their updates at your facility, as well as the re-training of employees. We will ascertain the adequacy of your corrections in our next inspection.\u003C\u002Fp>\n\n\u003Cp>We note that despite our positive findings of \u003Cem>Listeria\u003C\u002Fem> in your environment, your records show that you have not been able to find \u003Cem>Listeria\u003C\u002Fem> in your environment. We recommend that you review your \u003Cem>Listeria\u003C\u002Fem> monitoring plan, including the frequency and methodology of testing to find out why you have not been able to find \u003Cem>Listeria\u003C\u002Fem> in your environment. We also recommend that you review your cleaning frequency and methods to make sure your cleaning is adequate to control \u003Cem>Listeria\u003C\u002Fem> in your environment.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence of the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or \u003Cstrong>(b)(3)(A)\u003C\u002Fstrong> if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of the receipt of this letter, as to the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email at Lillian.aveta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald M. Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast – Division 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Sidney Chang\n\nRecipient Title\n\nPresident\n\nChang and Son Enterprises, Inc.\n\n301 River Road\n\nWhately, MA 01093\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 679517\n\n5\u002F31\u002F2024\n\nDear Mr. Chang,\n\nThe United States Food and Drug Administration (FDA) analyzed the environmental sample identified as sample 1245959, which consisted of 15 environmental swabs collected on December 20, 2023, from your sprouting operation at 301 River Road, Whately, MA, by the Commonwealth of Massachusetts Department of Agricultural Resources (MDAR) and determined that two of the fifteen swabs were positive for the presence of Listeria monocytogenes (L. monocytogenes), a human pathogen. Based on FDA’s analysis of the environmental samples, we have determined that your mung bean and soybean sprouts are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. Additionally, based on evaluation of whole genome sequence (WGS) analysis, we determined that the isolates from sample 1245959 match each other and 10 other L. monocytogenes that were isolated from several product samples collected from April 23, 2023, through December 4, 2023.\n\nBased on this evaluation, we have determined that your mung bean sprouts are contaminated within the meaning of section 402(a)(1) of the Act, 21 U.S.C. § 342(a)(1), in that they contain a poisonous or deleterious substance which may render them injurious to health. You can find the Act and its implementing regulations through internet links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nPathogen Findings\n\nL. monocytogenes is a pathogenic bacterium that is widespread in the environment and may be introduced into a sprouting operation from raw materials, humans, or equipment. Without proper sanitation practices, it can proliferate in a sprouting operation where it may contaminate food. Consuming food contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening illness called listeriosis, a foodborne illness, which is a major public health concern due to the severity of the disease, its high case-fatality rate, long incubation time, and tendency to affect individuals with underlying conditions.\n\nFDA’s analysis of the environmental swabs collected by MDAR on December 20, 2023, confirmed that two of the fifteen swabs were positive for L. monocytogenes. FDA also conducted WGS analysis on the environmental swabs taken by MDAR on December 20, 2023, and on the following samples of your mung bean sprouts:\n\na. On April 24, 2023, New York State - Agriculture and Markets (NYSAGM) Division of Food Safety and Inspection collected a sample of mung bean sprouts identified as sample: FL No. 2339630013 \u002F Lab No. 23B04362. The sample was collected at a retail store located in (b)(4), analyzed at the NYSAGM Division of Food Laboratory, and tested positive for L. monocytogenes.\n\nb. On May 4, 2023, MDAR conducted an inspection of your sprout operation and collected a sample of mung bean sprouts identified as Event Code: 05042023\u002FLab #: 23EN2354. The sample was analyzed by Massachusetts State Public Health Laboratory, and the sample tested positive for the human pathogen L. monocytogenes.\n\nc. On December 4, 2023, Virginia Department of Agriculture and Consumer Services (VDACS) Food Safety Program collected a sample of mung bean sprouts identified as sample: E231200179 (VDACS ID 992007932). This sample collected as part of the FDA\u002FState Laboratory Flexible Funding Model (LFFM) sampling program and was collected at a retail supermarket located in (b)(4). Sample was analyzed by the VDACS Division of Consolidated Laboratory Services and tested positive for L. monocytogenes.\n\nWGS analysis of bacterial human pathogens provides high-resolution data as it measures each DNA position in a bacterial genome, enabling direct links to be established between clinical isolates and food or environmental sources of bacterial contamination and illness. The WGS data can also be used to infer the evolutionary relationships (or phylogeny) of a given set of isolates. Six isolates identified in environmental sample 1245959 were found to match each other. These six isolates also matched ten isolates identified in the three product samples listed in the above descriptions, sample: FL No. 2339630013 \u002F Lab No. 23B04362, Event Code: 05042023\u002FLab #: 23EN2354, and E231200179 (VDACS ID 992007932). The high genetic similarity of the sixteen isolates and that they belong to the same strain suggests they likely came from the same source. The presence of L. monocytogenes in your operation is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your operation to prevent contamination of food.\n\nWe acknowledge that you initiated a recall on May 9, 2023, in response to the positive L. monocytogenes findings from MDAR from samples of your product collected on May 4, 2023, and that you initiated a recall on December 15, 2023 in response to the positive L. monocytogenes findings from VDACS from samples of your product collected on December 4, 2023.\n\nIn response to the above findings, FDA conducted an inspection of your sprouting operation located at 301 River Road., Whatley, Massachusetts, from January 10, 2024, through February 8, 2024, in accordance with Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption regulation (the Produce Safety Rule or PSR), Title 21, Code of Federal Regulations, Part 112 (21 CFR Part 112). We collected 91 environmental swabs, one of which, a sample from the bed of a truck outside your operation, yielded L. monocytogenes. At the close of the inspection, the FDA investigators issued your operation a Form FDA 483 (FDA-483), Inspectional Observations.\n\nWe acknowledge your written response to the FDA-483, received February 20, 2024. You stated that you have taken various corrective actions, including holding an employee meeting on the importance of following various sanitary practices, appointing an employee to monitor employee practices, informing your laboratories of discrepancies, and establishing processes with your laboratory regarding reporting sample discrepancies, sample issues, sending alternate samples, and checking results. You also explained various standard operating procedures and their updates at your facility, as well as the re-training of employees. We will ascertain the adequacy of your corrections in our next inspection.\n\nWe note that despite our positive findings of Listeria in your environment, your records show that you have not been able to find Listeria in your environment. We recommend that you review your Listeria monitoring plan, including the frequency and methodology of testing to find out why you have not been able to find Listeria in your environment. We also recommend that you review your cleaning frequency and methods to make sure your cleaning is adequate to control Listeria in your environment.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence of the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or (b)(3)(A) if criteria and conditions warrant.\n\nPlease notify this office in writing within 15 working days of the receipt of this letter, as to the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so.\n\nPlease send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email at Lillian.aveta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald M. Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast – Division 1","Chang and Son Enterprises, Inc.","chang-and-son-enterprises-inc-679517-05312024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchang-and-son-enterprises-inc-679517-05312024","2026-10-26T08:08:13.71396+00:00","2024-06-18","679517","Mr. Sidney Chang","2026-08-20T00:01:23.614+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-05-31",{"id":281,"raw":282,"subject":61,"body_html":287,"body_text":288,"firm_name":289,"letter_id":290,"created_at":86,"fei_number":19,"letter_url":291,"updated_at":292,"action_type":22,"case_status":23,"posted_date":293,"marcs_cms_no":294,"product_type":26,"closeout_date":19,"issuing_office":286,"recipient_name":295,"body_fetched_at":296,"delivery_method":297,"recipient_title":19,"reference_number":19,"action_taken_date":298,"medical_device_id":19,"response_letter_date":19},2894,[283,284,285,286,61,13,13,13],"\u003Ctime datetime=\"2022-02-01T14:20:00Z\">02\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-07T05:00:00Z\">01\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmolino-enterprises-one-inc-619323-01072022\">Molino Enterprises One, Inc.\u003C\u002Fa>","Division of Northeast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ronald Liriano-Marte\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Molino Enterprises One, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>392 E 197th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bronx\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10458-3702\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1\u002F7\u002F2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 619323\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Liriano-Marte:\u003C\u002Fp>\n\n\u003Cp>From August 10-September 14, 2021, the U.S. Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Molino Enterprises One, Inc., located at 392 E 197th Street, Bronx, NY 10458-3702. We also conducted an inspection on April 5, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: whole wheat breadsticks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, on September 14, 2021, our investigator provided you with a Form FDA 483a, FSVP Observations. To date, we have not received your response to the Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for whole wheat breadsticks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 619323 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Theresa Smedley\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRonald Liriano-Marte\n\nRecipient Title\n\nOwner\n\nMolino Enterprises One, Inc.\n\n392 E 197th Street\n\nBronx, NY 10458-3702\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\n1\u002F7\u002F2022\n\nRe: CMS # 619323\n\nDear Mr. Liriano-Marte:\n\nFrom August 10-September 14, 2021, the U.S. Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Molino Enterprises One, Inc., located at 392 E 197th Street, Bronx, NY 10458-3702. We also conducted an inspection on April 5, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: whole wheat breadsticks, (b)(4), and (b)(4) imported from your foreign supplier (b)(4) located in the (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, on September 14, 2021, our investigator provided you with a Form FDA 483a, FSVP Observations. To date, we have not received your response to the Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for whole wheat breadsticks, (b)(4), and (b)(4) imported from your foreign supplier (b)(4) located in the (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nAdditionally, we note that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\n\nPlease send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 619323 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTheresa Smedley\n\nActing Program Division Director\n\nDivision of Northeast Imports","Molino Enterprises One, Inc.","molino-enterprises-one-inc-619323-01072022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmolino-enterprises-one-inc-619323-01072022","2026-10-26T08:09:27.255692+00:00","2022-02-01","619323","Ronald Liriano-Marte","2026-08-20T02:13:21.081+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-01-07",{"id":300,"raw":301,"subject":307,"body_html":308,"body_text":309,"firm_name":310,"letter_id":311,"created_at":312,"fei_number":19,"letter_url":313,"updated_at":314,"action_type":22,"case_status":23,"posted_date":315,"marcs_cms_no":316,"product_type":317,"closeout_date":19,"issuing_office":305,"recipient_name":318,"body_fetched_at":319,"delivery_method":320,"recipient_title":19,"reference_number":19,"action_taken_date":321,"medical_device_id":19,"response_letter_date":19},22005,[302,303,304,305,306,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-26T04:00:00Z\">08\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpeter-schiff-enterprises-727888-08262026\">Peter Schiff Enterprises\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)\u003Cbr \u002F>\r\n","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Peter Schiff\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Peter Schiff Enterprises\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4400 Log Cabin Ln.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cookeville\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38506\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 727888\u003C\u002Fp>\u003Cp>August 26, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Schiff,\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Cookeville, TN from December 29, 2025, through December 31, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets cardiac electrode pads (Models 305L and 306L) and AC cardiac fibrillators (Model 310C). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are, among other things, intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and they do not achieve their primary intended purposes through chemical action within or on the body of man or other animals and are not dependent upon being metabolized for the achievement of their primary intended purposes.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your Model 310C Fibrillator and Models 305L and 306L cardiac electrode pad devices are adulterated under section 501(f)(1) of the Act, 21 U.S.C. § 351(f)(1), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a). The introduction or delivery for introduction into interstate commerce, or causing thereof, of any device that is adulterated or misbranded is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>Your firm asserts that the Model 310C Fibrillator is an unclassified pre-amendments device and you have listed it under product code LIW. However, the FDA inspection found that the device has been significantly modified since its introduction in 1966 into interstate commerce. Modifications include changes to the battery type and housing, changing from an analog system to a digital platform, increase of the voltage output specifications, and change in electrode placement. As described at page 10 of the FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device”, “[m]anufacturers should conduct a risk-based assessment that compares the changed device to...their preamendments device...When the cumulative effect of individual changes triggers the regulatory threshold for submission, the manufacturer should submit a new 510(k).” The preamendments device uses two replaceable Mallory RM12R mercury batteries, a variable 0-7 volt output, and electrodes that are intended to be positioned under the ventricles. In contrast, the current version of your device uses a nonreplaceable lithium battery, fixed 9 or 18 volt output, and electrode pads that are placed under the myocardium. The current version also features an automatic 30-minute shutoff which indicates that the device has been updated from analog to digital. Your firm’s introduction of these updates represents changes or modifications that could significantly affect the safety or effectiveness of your device. See 21 CFR 807.81(a)(3).\u003C\u002Fp>\u003Cp>For example, the different battery, voltage output, pads placement, and update from analog to digital, cumulatively increase the risk of injury associated with use of the device, such as burns, irritation or inflammation, pain, fever, toxicity that leads to tissue damage and\u002For loss of organ function or failure, etc. The design of the device is significantly changed from the original preamendments device due to these modifications. The changes should be appropriately verified and\u002For validated in accordance with the Quality Management System Regulation (QMSR) (21 CFR part 820) to ensure adequate performance. Inadequate performance may result in serious patient harm such as delay in procedure or failure to induce ventricular fibrillation as intended during open heart surgery on vulnerable patients, including critically ill cardiac surgery patients and pediatric patients undergoing congenital heart defect repairs.\u003C\u002Fp>\u003Cp>Your firm asserts that the Models 305L and 306L cardiac electrode pads fall within the scope of 21 CFR 890.1175 Electrode cable and are exempt from premarket notification. Generic devices of this type are typically composed of strands of insulated electrical conductors laid together around a central core and intended for medical purposes to connect an electrode from a patient to a diagnostic machine. However, the Models 305L and 306L cardiac electrode pads are intended to connect a fibrillator to cardiac tissue and do not have a diagnostic function. They are, therefore, not exempt from pre-market notification because they are not the type of device that is within the generic category of devices identified under 21 CFR 890.1175.\u003C\u002Fp>\u003Cp>In order to allow FDA to formally determine the appropriate classification of your devices, FDA recommends submission of a 513(g) Request for Information to obtain a formal response from FDA. For instructions on how to submit a 513(g) Request, please refer to the following guidance document: \u003Cu>FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act | FDA.\u003C\u002Fu>\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that you need to submit in order to obtain approval or clearance authorization for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002Fcdrh\u002Fdevadvice\u002F3122.html. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, CFR, part 820. We received responses from Peter Schiff, Owner, dated January 11, 2026 and June 16, 2026, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. The violations found during the inspection include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. For example,\u003C\u002Fp>\u003Cp>a. On December 29, 2025, the Quality Control Manager stated that your firm does not have a purchasing control procedure that would evaluate and define the type and extent of control to be exercised over suppliers, and that you have no quality agreements with any of the suppliers on the Approved Supplier List (ASL) that would dictate the level of control that the company has over the supplier, including requirements for suppliers to notify your firm of any changes to the materials used in manufacturing the components.\u003C\u002Fp>\u003Cp>Furthermore, according to the Quality Control Manager, supplier selection is performed by the owner of your firm without documented procedures or documentation of quality requirements used in the selection process. For example, your firm has not performed a qualification or evaluation of your supplier of stainless-steel electrode cups used in the manufacture of the adult and pediatric cardiac electrode pads.\u003C\u002Fp>\u003Cp>b. The firm does not have documented specified requirements, including quality requirements, for materials used in the cardiac electrode pad manufacturing process, including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> that are purchased at local grocery\u002Fdepartment stores and used during the cleaning process of the stainless-steel button on adult and pediatric electro pads. No specifications or quality requirements exist for these materials despite their direct contact with the finished medical device.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> purchased at local home improvement stores and used during the manufacturing process to clean the finished devices in a series of rinses in \u003Cstrong>(b)(4) \u003C\u002Fstrong>baths. No supplier qualification or acceptance criteria exist for this cleaning agent.\u003C\u002Fli>\u003Cli>Silicone materials used in the manufacturing of the cardiac electrode pads. The safety data sheets (SDS) mentioned the materials are “Not for internal or medical use” and “Industrial mold making. Not for internal or medical use.”\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> material used in the manufacturing of the cardiac electrode pads. During the inspection, the Investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the walkthrough of the facility which is used in the preparation of the lead wires for the electrode pad production.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm has not completed a biocompatibility assessment (i.e., biocompatibility testing or rationale for why biocompatibility testing is not necessary). An adequate biocompatibility assessment is important because patient or user exposure to your device could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to tissue damage and\u002For loss of organ function or failure. Specifically, FDA is concerned that the use of non-medical grade materials may result in increased levels of impurities as well as inconsistencies in the quality and safety of the materials used due to inadequate manufacturing controls. The use of non-medical grade materials and lack of biological testing may result in adverse health effects described above. Your firm should identify the tissue contacting components and materials of the device, including the chemical name, trade name, suppliers, dimensions\u002Fsurface area (or amount if applicable), and whether the components have direct, indirect, or no contact with the patient’s circulating blood, tissue, and\u002For skin, as well as their expected duration of contact (e.g., transitory, limited, permanent, etc.). (See Section III Attachment F of FDA’s Biocompatibility Guidance “Use of International Standard ISO 10993-1, ‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process,’\" (https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F142959\u002Fdownload).) In addition, your firm should provide methods and results from biocompatibility testing of the subject device according to a recognized standard, and as recommended in Attachment A of FDA’s Biocompatibility Guidance for devices with the subject device’s nature and duration of tissue contact. The cardiac fibrillator device is an external communicating device that has either direct tissue contact or indirect circulating blood contact with the patient for less than 24 hours. In accordance with ISO 10993 part 1, for this type of product, CDRH recommends the following tests be considered: cytotoxicity, sensitization (guinea pig maximization with both polar and non-polar extracts), intracutaneous reactivity, acute systemic toxicity, material mediated pyrogenicity, and extract hemolysis (if indirect circulating blood contact).\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example, your firm has not established design control procedures. Furthermore, your firm failed to follow Section 9 of the firm’s Quality Manual, effective 6\u002F1\u002F2020, which requires a Design History File for Adult Cardiac Electrode Pad (Model 305L), Pediatric Cardiac Electrode Pad (306L) and Cardiac Fibrillator (Model 310C).\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example:\u003C\u002Fp>\u003Cp>a. Your firm’s owner indicated that he receives “feedback” from customers involving the battery not starting on Cardiac Fibrillators manufactured by the firm. This “feedback” meets the definition of a complaint, as defined by 21 CFR 820.3(b), and was not documented as such.\u003C\u002Fp>\u003Cp>b. Your firm maintains an uncontrolled document titled “Complaint Handling” that is used as the complaint handling procedure. This procedure lacks the definition of a complaint and it lacks requirements for:\u003Cbr>1) Uniform and timely processing of complaints.\u003C\u002Fp>\u003Cp>2) Evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803 (Medical Device Reporting).\u003C\u002Fp>\u003Cp>3) Evaluation of complaints to determine whether an investigation is necessary.\u003C\u002Fp>\u003Cp>4) Ensuring any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications be reviewed, evaluated, and investigated, unless such investigation has already been performed for a similar complaint and another investigation is not necessary.\u003C\u002Fp>\u003Cp>5) The elements that must be included in the record of investigation when an investigation is made including, but not limited to:\u003Cbr>&nbsp; &nbsp; (1) The name of the device.\u003Cbr>&nbsp; &nbsp; (2) The date the complaint was received.\u003Cbr>&nbsp; &nbsp; (3) Any unique device identifier (UDI) or universal product code (UPC) and any other device identification(s)\u002Fcontrol number(s) used.\u003Cbr>&nbsp; &nbsp; (4) The name, address, and phone number of the complainant.\u003Cbr>&nbsp; &nbsp; (5) The nature and details of the complaint.\u003Cbr>&nbsp; &nbsp; (6) The dates and results of the investigation.\u003Cbr>&nbsp; &nbsp; (7) Any corrective action taken.\u003Cbr>&nbsp; &nbsp; (8) Any reply to the complainant.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>4. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm failed to investigate the causes of nonconformities as well as document the corrective actions taken to address nonconformities. For example, your firm took the corrective action to address the 2017 FDA Observation 1 which consisted of using a contract sterilizer to perform sterilization validation for the Adult Electrode Pads (Model 305L) and Pediatric Electrode Pads (Model 306L). However, your firm failed to document the review of the validation sterilization report to verify that the corrective action taken was effective at validating the parameters listed within the instructions for use.\u003C\u002Fp>\u003Cp>\u003Cstrong>This is a repeat observation from the 2017, 2013, and 2011 FDA inspections.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\u003C\u002Fp>\u003Cp>a. Your firm’s nonconformance procedure located within the Device History Records Procedures Manual, Doc #18-12\u002F20\u002F2025, fails to adequately establish how nonconforming product is documented, evaluated, and dispositioned. The procedure also lacks the requirement to determine the need for an investigation and notification of the persons or organizations responsible for the nonconformance. For example, production records for the cardiac electrode pads such as the following did not have a documented evaluation to determine the need for an investigation:\u003C\u002Fp>\u003Cul>\u003Cli>Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> poured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting in 1 non-conforming unit with rust on the electrodes.\u003C\u002Fli>\u003Cli>Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> poured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting in 1 non-conforming unit with rust on the electrodes.\u003C\u002Fli>\u003Cli>Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> poured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting in 1 non-conforming unit with sunken electrodes and no QA release signature.\u003C\u002Fli>\u003Cli>Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> poured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting in 1 non-conforming unit with sunken electrodes.\u003C\u002Fli>\u003Cli>Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> poured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting in 1 non-conforming unit with unsecured wire.\u003C\u002Fli>\u003Cli>Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> poured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting in 1 non-conforming unit with unsecured wire and no QA release signature.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, there is no documentation indicating that Adult Electrode Pads (Model 305L) and Pediatric Electrode Pads (Model 306L) rejected units have been reviewed and evaluated, or that disposition decisions have been made and approved by\u003Cbr>authorized personnel. Production records only document the quantity produced and quantity accepted, with vague descriptors for rejected units.\u003C\u002Fp>\u003Cp>b. Your firm’s Quality Control Manager indicated that wires from non-conforming Adult Electrode Pads (Model 305L) and Pediatric Electrode Pads (Model 306L) are routinely cut and reused in the production of new electrode pads, while the \u003Cstrong>(b)(4)\u003C\u002Fstrong> are discarded. This rework is not documented, and there is no evidence that the rework has been evaluated and approved, or that reworked product has been verified to meet specified requirements before being returned to production.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d). For example,\u003C\u002Fp>\u003Cp>a. Your firm released and distributed electrode pads from lot numbers \u003Cstrong>(b)(4) \u003C\u002Fstrong>manufactured between 11\u002F3-12\u002F5\u002F2025 without the Quality Control Manager completing a final inspection of the product and label as required by procedure, Doc #18, Device History Records Procedures Manual, dated 12\u002F20\u002F2025.\u003C\u002Fp>\u003Cp>b. The firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and assigned them lot number \u003Cstrong>(b)(4) \u003C\u002Fstrong>despite your firm indicating that each lot number should be assigned a sequential number. The firm’s Quality Manager indicated she did not know what happened and did not know which product was distributed to the customer located in \u003Cstrong>(b)(4) \u003C\u002Fstrong>on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. The firm has been releasing and distributing finished products with labeling showing an incorrect email for contacting the firm since March 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>This is a repeat observation from the 2013 FDA inspection.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>7. Failure to adequately establish procedures for quality audits, as required by 21 CFR 820.22.\u003Cbr>For example,\u003C\u002Fp>\u003Cp>a. Your firm’s document titled “Quality Manual”, Doc # 14, Effective 06\u002F01\u002F2020 states in section 15 that internal audits are to be conducted “periodically to verify compliance with the QMS and FDA requirements.” The Quality Control Manager stated during the\u003Cbr>inspection on December 29, 2025, that no internal audits have been conducted by your firm and that the first audit is scheduled for January of 2026 despite your firm being in operation since 1966.\u003C\u002Fp>\u003Cp>b. Your firm’s Quality Manual, which includes internal audit requirements fails to: establish a frequency for conducting internal audits; include auditing criteria; include the regulatory requirement that quality audits be conducted by individuals who do not have direct responsibility for the matters being audited; and the potential for reaudits if needed.\u003C\u002Fp>\u003Cp>\u003Cstrong>This is a repeat observation from the 2017, 2013, and 2011 FDA inspections.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>8. Failure to adequately establish procedures for management review, as required by 21 CFR 820.20(c). For example, the Quality Manual (Doc #14, dated 06\u002F01\u002F2020) describes in section 16 the criteria for conducting management reviews at planned intervals. Your firm has not performed management reviews despite the firm being in operation since 1966.\u003C\u002Fp>\u003Cp>\u003Cstrong>This is a repeat observation from the 2017, 2013, and 2011 FDA inspections.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>9. Failure to adequately maintain a device history record, as required by 21 CFR 820.184. For example,\u003C\u002Fp>\u003Cp>a. The Device History Records (DHRs) do not include or refer to the location of the label and labeling used for each production run, lot, or batch of finished devices.\u003C\u002Fp>\u003Cp>b. The DHRs do not include records of examination and release of device labeling, including the date and signature of the individual(s) performing the examination for production lots as evidenced by Cardiac Electrode Pad lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. The DHR for Cardiac Electrode Pad lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was released by the Quality Control Manager, however manufacturing steps for continuity check after assembly, and subsequent cleaning and packaging activities were not documented as completed, which is required for release of finished product.\u003C\u002Fp>\u003Cp>\u003Cstrong>This is a repeat observation from the 2017 and 2011 FDA inspections.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to develop and maintain any written MDR procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\u003Cp>\u003Cstrong>This is a repeat observation from the 2011 FDA inspection.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\u003C\u002Fp>\u003Cp>The failure to establish or maintain any record, or make any report, required under section 519 of the Act, 21 U.S.C. § 360i, is prohibited under section 301(e) of the Act, 21 U.S.C. § 331(e).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification (UDI) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of the Act, specifically, under section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830. The labels of the Pediatric (Model 306L) and Adult (Model 305L) cardiac electrode pad and AC cardiac fibrillator (Model 310C) devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for the devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)). Your firm’s responses do not demonstrate that your devices have compliant labeling.\u003C\u002Fp>\u003Cp>In addition, the Pediatric (Model 306L) and Adult (Model 305L) cardiac electrode pad and AC cardiac fibrillator (Model 310C) devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i and implementing regulations set forth in 21 CFR part 830, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR part 830, subpart E, respecting these devices. The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>Based on our review of the Global Unique Device Identification Database (GUDID), there are no entries for your devices. Your responses do not address this concern.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection, from December 29, 2025, through December 31, 2025, was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage:\u003Cbr>\u003Cstrong>Quality Management System Regulation – Frequently Asked Questions | FDA\u003C\u002Fstrong>\u003Cbr>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>We are requesting that you submit to this office, on the schedule below, certification by an outside expert consultant that he or she has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality Management System Regulation (21 CFR part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\u003Cul>\u003Cli>Initial certifications by consultant and establishment – February 26, 2027\u003C\u002Fli>\u003Cli>Subsequent certifications – February 26, 2028 and February 26, 2029\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727888” when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, Ashley.Mutawakkil@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003Cbr>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPeter Schiff\n\nRecipient Title\n\nOwner\n\nPeter Schiff Enterprises\n\n4400 Log Cabin Ln.\n\nCookeville, TN 38506\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 727888\nAugust 26, 2026\nDear Mr. Schiff,\nDuring an inspection of your firm located in Cookeville, TN from December 29, 2025, through December 31, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets cardiac electrode pads (Models 305L and 306L) and AC cardiac fibrillators (Model 310C). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are, among other things, intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and they do not achieve their primary intended purposes through chemical action within or on the body of man or other animals and are not dependent upon being metabolized for the achievement of their primary intended purposes.\nUnapproved Device Violation\nOur inspection revealed that your Model 310C Fibrillator and Models 305L and 306L cardiac electrode pad devices are adulterated under section 501(f)(1) of the Act, 21 U.S.C. § 351(f)(1), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a). The introduction or delivery for introduction into interstate commerce, or causing thereof, of any device that is adulterated or misbranded is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\nYour firm asserts that the Model 310C Fibrillator is an unclassified pre-amendments device and you have listed it under product code LIW. However, the FDA inspection found that the device has been significantly modified since its introduction in 1966 into interstate commerce. Modifications include changes to the battery type and housing, changing from an analog system to a digital platform, increase of the voltage output specifications, and change in electrode placement. As described at page 10 of the FDA guidance document, “Deciding When to Submit a 510(k) for a Change to an Existing Device”, “[m]anufacturers should conduct a risk-based assessment that compares the changed device to...their preamendments device...When the cumulative effect of individual changes triggers the regulatory threshold for submission, the manufacturer should submit a new 510(k).” The preamendments device uses two replaceable Mallory RM12R mercury batteries, a variable 0-7 volt output, and electrodes that are intended to be positioned under the ventricles. In contrast, the current version of your device uses a nonreplaceable lithium battery, fixed 9 or 18 volt output, and electrode pads that are placed under the myocardium. The current version also features an automatic 30-minute shutoff which indicates that the device has been updated from analog to digital. Your firm’s introduction of these updates represents changes or modifications that could significantly affect the safety or effectiveness of your device. See 21 CFR 807.81(a)(3).\nFor example, the different battery, voltage output, pads placement, and update from analog to digital, cumulatively increase the risk of injury associated with use of the device, such as burns, irritation or inflammation, pain, fever, toxicity that leads to tissue damage and\u002For loss of organ function or failure, etc. The design of the device is significantly changed from the original preamendments device due to these modifications. The changes should be appropriately verified and\u002For validated in accordance with the Quality Management System Regulation (QMSR) (21 CFR part 820) to ensure adequate performance. Inadequate performance may result in serious patient harm such as delay in procedure or failure to induce ventricular fibrillation as intended during open heart surgery on vulnerable patients, including critically ill cardiac surgery patients and pediatric patients undergoing congenital heart defect repairs.\nYour firm asserts that the Models 305L and 306L cardiac electrode pads fall within the scope of 21 CFR 890.1175 Electrode cable and are exempt from premarket notification. Generic devices of this type are typically composed of strands of insulated electrical conductors laid together around a central core and intended for medical purposes to connect an electrode from a patient to a diagnostic machine. However, the Models 305L and 306L cardiac electrode pads are intended to connect a fibrillator to cardiac tissue and do not have a diagnostic function. They are, therefore, not exempt from pre-market notification because they are not the type of device that is within the generic category of devices identified under 21 CFR 890.1175.\nIn order to allow FDA to formally determine the appropriate classification of your devices, FDA recommends submission of a 513(g) Request for Information to obtain a formal response from FDA. For instructions on how to submit a 513(g) Request, please refer to the following guidance document: FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act | FDA.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that you need to submit in order to obtain approval or clearance authorization for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002Fcdrh\u002Fdevadvice\u002F3122.html. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, CFR, part 820. We received responses from Peter Schiff, Owner, dated January 11, 2026 and June 16, 2026, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. The violations found during the inspection include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50. For example,\na. On December 29, 2025, the Quality Control Manager stated that your firm does not have a purchasing control procedure that would evaluate and define the type and extent of control to be exercised over suppliers, and that you have no quality agreements with any of the suppliers on the Approved Supplier List (ASL) that would dictate the level of control that the company has over the supplier, including requirements for suppliers to notify your firm of any changes to the materials used in manufacturing the components.\nFurthermore, according to the Quality Control Manager, supplier selection is performed by the owner of your firm without documented procedures or documentation of quality requirements used in the selection process. For example, your firm has not performed a qualification or evaluation of your supplier of stainless-steel electrode cups used in the manufacture of the adult and pediatric cardiac electrode pads.\nb. The firm does not have documented specified requirements, including quality requirements, for materials used in the cardiac electrode pad manufacturing process, including but not limited to:\n(b)(4) that are purchased at local grocery\u002Fdepartment stores and used during the cleaning process of the stainless-steel button on adult and pediatric electro pads. No specifications or quality requirements exist for these materials despite their direct contact with the finished medical device.\n(b)(4) purchased at local home improvement stores and used during the manufacturing process to clean the finished devices in a series of rinses in (b)(4) baths. No supplier qualification or acceptance criteria exist for this cleaning agent.\nSilicone materials used in the manufacturing of the cardiac electrode pads. The safety data sheets (SDS) mentioned the materials are “Not for internal or medical use” and “Industrial mold making. Not for internal or medical use.”\n(b)(4) material used in the manufacturing of the cardiac electrode pads. During the inspection, the Investigators observed (b)(4) containing (b)(4) during the walkthrough of the facility which is used in the preparation of the lead wires for the electrode pad production.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm has not completed a biocompatibility assessment (i.e., biocompatibility testing or rationale for why biocompatibility testing is not necessary). An adequate biocompatibility assessment is important because patient or user exposure to your device could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to tissue damage and\u002For loss of organ function or failure. Specifically, FDA is concerned that the use of non-medical grade materials may result in increased levels of impurities as well as inconsistencies in the quality and safety of the materials used due to inadequate manufacturing controls. The use of non-medical grade materials and lack of biological testing may result in adverse health effects described above. Your firm should identify the tissue contacting components and materials of the device, including the chemical name, trade name, suppliers, dimensions\u002Fsurface area (or amount if applicable), and whether the components have direct, indirect, or no contact with the patient’s circulating blood, tissue, and\u002For skin, as well as their expected duration of contact (e.g., transitory, limited, permanent, etc.). (See Section III Attachment F of FDA’s Biocompatibility Guidance “Use of International Standard ISO 10993-1, ‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process,’\" (https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F142959\u002Fdownload).) In addition, your firm should provide methods and results from biocompatibility testing of the subject device according to a recognized standard, and as recommended in Attachment A of FDA’s Biocompatibility Guidance for devices with the subject device’s nature and duration of tissue contact. The cardiac fibrillator device is an external communicating device that has either direct tissue contact or indirect circulating blood contact with the patient for less than 24 hours. In accordance with ISO 10993 part 1, for this type of product, CDRH recommends the following tests be considered: cytotoxicity, sensitization (guinea pig maximization with both polar and non-polar extracts), intracutaneous reactivity, acute systemic toxicity, material mediated pyrogenicity, and extract hemolysis (if indirect circulating blood contact).\n2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example, your firm has not established design control procedures. Furthermore, your firm failed to follow Section 9 of the firm’s Quality Manual, effective 6\u002F1\u002F2020, which requires a Design History File for Adult Cardiac Electrode Pad (Model 305L), Pediatric Cardiac Electrode Pad (306L) and Cardiac Fibrillator (Model 310C).\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n3. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example:\na. Your firm’s owner indicated that he receives “feedback” from customers involving the battery not starting on Cardiac Fibrillators manufactured by the firm. This “feedback” meets the definition of a complaint, as defined by 21 CFR 820.3(b), and was not documented as such.\nb. Your firm maintains an uncontrolled document titled “Complaint Handling” that is used as the complaint handling procedure. This procedure lacks the definition of a complaint and it lacks requirements for:\n1) Uniform and timely processing of complaints.\n2) Evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803 (Medical Device Reporting).\n3) Evaluation of complaints to determine whether an investigation is necessary.\n4) Ensuring any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications be reviewed, evaluated, and investigated, unless such investigation has already been performed for a similar complaint and another investigation is not necessary.\n5) The elements that must be included in the record of investigation when an investigation is made including, but not limited to:\n(1) The name of the device.\n(2) The date the complaint was received.\n(3) Any unique device identifier (UDI) or universal product code (UPC) and any other device identification(s)\u002Fcontrol number(s) used.\n(4) The name, address, and phone number of the complainant.\n(5) The nature and details of the complaint.\n(6) The dates and results of the investigation.\n(7) Any corrective action taken.\n(8) Any reply to the complainant.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n4. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm failed to investigate the causes of nonconformities as well as document the corrective actions taken to address nonconformities. For example, your firm took the corrective action to address the 2017 FDA Observation 1 which consisted of using a contract sterilizer to perform sterilization validation for the Adult Electrode Pads (Model 305L) and Pediatric Electrode Pads (Model 306L). However, your firm failed to document the review of the validation sterilization report to verify that the corrective action taken was effective at validating the parameters listed within the instructions for use.\nThis is a repeat observation from the 2017, 2013, and 2011 FDA inspections.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n5. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\na. Your firm’s nonconformance procedure located within the Device History Records Procedures Manual, Doc #18-12\u002F20\u002F2025, fails to adequately establish how nonconforming product is documented, evaluated, and dispositioned. The procedure also lacks the requirement to determine the need for an investigation and notification of the persons or organizations responsible for the nonconformance. For example, production records for the cardiac electrode pads such as the following did not have a documented evaluation to determine the need for an investigation:\nLot (b)(4) poured on (b)(4) resulting in 1 non-conforming unit with rust on the electrodes.\nLot (b)(4) poured on (b)(4) resulting in 1 non-conforming unit with rust on the electrodes.\nLot (b)(4) poured on (b)(4) resulting in 1 non-conforming unit with sunken electrodes and no QA release signature.\nLot (b)(4) poured on (b)(4) resulting in 1 non-conforming unit with sunken electrodes.\nLot (b)(4) poured on (b)(4) resulting in 1 non-conforming unit with unsecured wire.\nLot (b)(4) poured on (b)(4) resulting in 1 non-conforming unit with unsecured wire and no QA release signature.\nFurthermore, there is no documentation indicating that Adult Electrode Pads (Model 305L) and Pediatric Electrode Pads (Model 306L) rejected units have been reviewed and evaluated, or that disposition decisions have been made and approved by\nauthorized personnel. Production records only document the quantity produced and quantity accepted, with vague descriptors for rejected units.\nb. Your firm’s Quality Control Manager indicated that wires from non-conforming Adult Electrode Pads (Model 305L) and Pediatric Electrode Pads (Model 306L) are routinely cut and reused in the production of new electrode pads, while the (b)(4) are discarded. This rework is not documented, and there is no evidence that the rework has been evaluated and approved, or that reworked product has been verified to meet specified requirements before being returned to production.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n6. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d). For example,\na. Your firm released and distributed electrode pads from lot numbers (b)(4) manufactured between 11\u002F3-12\u002F5\u002F2025 without the Quality Control Manager completing a final inspection of the product and label as required by procedure, Doc #18, Device History Records Procedures Manual, dated 12\u002F20\u002F2025.\nb. The firm manufactured (b)(4) lots on (b)(4) and assigned them lot number (b)(4) despite your firm indicating that each lot number should be assigned a sequential number. The firm’s Quality Manager indicated she did not know what happened and did not know which product was distributed to the customer located in (b)(4) on (b)(4).\nc. The firm has been releasing and distributing finished products with labeling showing an incorrect email for contacting the firm since March 2025.\nThis is a repeat observation from the 2013 FDA inspection.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n7. Failure to adequately establish procedures for quality audits, as required by 21 CFR 820.22.\nFor example,\na. Your firm’s document titled “Quality Manual”, Doc # 14, Effective 06\u002F01\u002F2020 states in section 15 that internal audits are to be conducted “periodically to verify compliance with the QMS and FDA requirements.” The Quality Control Manager stated during the\ninspection on December 29, 2025, that no internal audits have been conducted by your firm and that the first audit is scheduled for January of 2026 despite your firm being in operation since 1966.\nb. Your firm’s Quality Manual, which includes internal audit requirements fails to: establish a frequency for conducting internal audits; include auditing criteria; include the regulatory requirement that quality audits be conducted by individuals who do not have direct responsibility for the matters being audited; and the potential for reaudits if needed.\nThis is a repeat observation from the 2017, 2013, and 2011 FDA inspections.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n8. Failure to adequately establish procedures for management review, as required by 21 CFR 820.20(c). For example, the Quality Manual (Doc #14, dated 06\u002F01\u002F2020) describes in section 16 the criteria for conducting management reviews at planned intervals. Your firm has not performed management reviews despite the firm being in operation since 1966.\nThis is a repeat observation from the 2017, 2013, and 2011 FDA inspections.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\n9. Failure to adequately maintain a device history record, as required by 21 CFR 820.184. For example,\na. The Device History Records (DHRs) do not include or refer to the location of the label and labeling used for each production run, lot, or batch of finished devices.\nb. The DHRs do not include records of examination and release of device labeling, including the date and signature of the individual(s) performing the examination for production lots as evidenced by Cardiac Electrode Pad lots (b)(4), and (b)(4).\nc. The DHR for Cardiac Electrode Pad lot (b)(4) was released by the Quality Control Manager, however manufacturing steps for continuity check after assembly, and subsequent cleaning and packaging activities were not documented as completed, which is required for release of finished product.\nThis is a repeat observation from the 2017 and 2011 FDA inspections.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\nMedical Device Reporting (MDR) Violation\nOur inspection also revealed that your firm failed to develop and maintain any written MDR procedures, as required by 21 CFR 803.17.\nThis is a repeat observation from the 2011 FDA inspection.\nWe reviewed your firm’s responses and conclude that they are not adequate. They do not address any FDA 483 observation corrective action plans or timeframes for coming into compliance.\nThe failure to establish or maintain any record, or make any report, required under section 519 of the Act, 21 U.S.C. § 360i, is prohibited under section 301(e) of the Act, 21 U.S.C. § 331(e).\nUnique Device Identification (UDI) Violations\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of the Act, specifically, under section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR part 801, subpart B, and 21 CFR part 830. The labels of the Pediatric (Model 306L) and Adult (Model 305L) cardiac electrode pad and AC cardiac fibrillator (Model 310C) devices do not bear such a UDI.\nSpecifically, the labels for the devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)). Your firm’s responses do not demonstrate that your devices have compliant labeling.\nIn addition, the Pediatric (Model 306L) and Adult (Model 305L) cardiac electrode pad and AC cardiac fibrillator (Model 310C) devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i and implementing regulations set forth in 21 CFR part 830, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR part 830, subpart E, respecting these devices. The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nBased on our review of the Global Unique Device Identification Database (GUDID), there are no entries for your devices. Your responses do not address this concern.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection, from December 29, 2025, through December 31, 2025, was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage:\nQuality Management System Regulation – Frequently Asked Questions | FDA\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nWe are requesting that you submit to this office, on the schedule below, certification by an outside expert consultant that he or she has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality Management System Regulation (21 CFR part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\nInitial certifications by consultant and establishment – February 26, 2027\nSubsequent certifications – February 26, 2028 and February 26, 2029\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727888” when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, Ashley.Mutawakkil@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Peter Schiff Enterprises","peter-schiff-enterprises-727888-08262026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpeter-schiff-enterprises-727888-08262026","2026-11-17T01:02:03.701861+00:00","2026-10-27","727888","Medical Devices","Peter Schiff","2026-11-03T01:02:52.857+00:00","VIA Electronic Mail","2026-08-26",{"id":323,"raw":324,"subject":121,"body_html":328,"body_text":329,"firm_name":330,"letter_id":331,"created_at":147,"fei_number":19,"letter_url":332,"updated_at":333,"action_type":22,"case_status":23,"posted_date":334,"marcs_cms_no":335,"product_type":130,"closeout_date":19,"issuing_office":120,"recipient_name":336,"body_fetched_at":337,"delivery_method":133,"recipient_title":19,"reference_number":338,"action_taken_date":339,"medical_device_id":19,"response_letter_date":19},1422,[325,326,327,120,121,13,13,13],"\u003Ctime datetime=\"2024-06-13T04:00:00Z\">06\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-12T04:00:00Z\">06\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiz-pump-llc-dba-puffin-enterprises-685568-06122024\">Biz Pump LLC d\u002Fb\u002Fa Puffin Enterprises\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402160\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zackary J Muller\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Biz Pump LLC d\u002Fb\u002Fa Puffin Enterprises\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4578 Royal Palm Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@puffinvapeshop.com\"> info@puffinvapeshop.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Zackary J Muller:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.puffinvapeshop.com and determined that electronic nicotine delivery system (ENDS) and e-liquid products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS and e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS and e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS and e-liquid products that lack a marketing authorization order: Cereal Trip by Bad Drip Series 60mL, Don’t Care Bear by Bad Drip Series 60mL, and Funky Republic Fi3000 Disposable 3000 Puff 5mL 40-50mg - Apple Watermelon.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds some of these products particularly concerning because the design of the Bad Drip Labs e-liquid products (see Exhibits A) are likely to appeal to youth by imitating a prescription pill bottle (see Exhibits B). Specifically, the overall presentation of the e-liquid products, including the graphical elements on their labeling and\u002For advertising, makes it appear that the products are a prescription and could reasonably result in a child or adult ingesting the products. Further, the products are likely to appeal to youth because they enable youth to conceal a tobacco product from parents, teachers, or other adults. FDA is concerned about the rising youth appeal and dramatic rise in youth use of e-liquid products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with e-liquid products.\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F685568.PNG\" alt=\"Pill Bottles\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F685568-2.PNG\" alt=\"Pill Bottles\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003Cbr>\n\u003Cbr>\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402160, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Atencio\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Biz Pump LLC\u003Cbr>\nAttn: Katherine Vasquez\u003Cbr>\n11195 SW 1st #219\u003Cbr>\nMiami, FL, 33176\u003C\u002Fp>\n\n\u003Cp>Biz Pump LLC\u003Cbr>\nAttn: Oriahn Ben Yakar\u003Cbr>\n5140 North 37 ST\u003Cbr>\nHollywood, FL, 33021\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402160\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nZackary J Muller\n\nBiz Pump LLC d\u002Fb\u002Fa Puffin Enterprises\n\n4578 Royal Palm Ave\n\nMiami, FL 33140\n\nUnited States\n\ninfo@puffinvapeshop.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 12, 2024\n\nWARNING LETTER\n\nDear Zackary J Muller:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.puffinvapeshop.com and determined that electronic nicotine delivery system (ENDS) and e-liquid products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS and e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS and e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS and e-liquid products that lack a marketing authorization order: Cereal Trip by Bad Drip Series 60mL, Don’t Care Bear by Bad Drip Series 60mL, and Funky Republic Fi3000 Disposable 3000 Puff 5mL 40-50mg - Apple Watermelon.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nAdditional Considerations\n\nFDA finds some of these products particularly concerning because the design of the Bad Drip Labs e-liquid products (see Exhibits A) are likely to appeal to youth by imitating a prescription pill bottle (see Exhibits B). Specifically, the overall presentation of the e-liquid products, including the graphical elements on their labeling and\u002For advertising, makes it appear that the products are a prescription and could reasonably result in a child or adult ingesting the products. Further, the products are likely to appeal to youth because they enable youth to conceal a tobacco product from parents, teachers, or other adults. FDA is concerned about the rising youth appeal and dramatic rise in youth use of e-liquid products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with e-liquid products.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402160, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Atencio\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nBiz Pump LLC\n\nAttn: Katherine Vasquez\n\n11195 SW 1st #219\n\nMiami, FL, 33176\n\nBiz Pump LLC\n\nAttn: Oriahn Ben Yakar\n\n5140 North 37 ST\n\nHollywood, FL, 33021\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","Biz Pump LLC d\u002Fb\u002Fa Puffin Enterprises","biz-pump-llc-dba-puffin-enterprises-685568-06122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiz-pump-llc-dba-puffin-enterprises-685568-06122024","2026-10-26T08:08:05.70121+00:00","2024-06-13","685568","Zackary J Muller","2026-08-20T00:02:12.178+00:00","RW2402160","2024-06-12",{"id":341,"raw":342,"subject":61,"body_html":346,"body_text":347,"firm_name":348,"letter_id":349,"created_at":350,"fei_number":19,"letter_url":351,"updated_at":352,"action_type":22,"case_status":23,"posted_date":353,"marcs_cms_no":354,"product_type":26,"closeout_date":19,"issuing_office":60,"recipient_name":355,"body_fetched_at":356,"delivery_method":237,"recipient_title":19,"reference_number":19,"action_taken_date":357,"medical_device_id":19,"response_letter_date":19},165,[343,344,345,60,61,13,13,13],"\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-29T04:00:00Z\">04\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsahara-enterprise-inc-728927-04292026\">Sahara Enterprise Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Khalid A. Zaidan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sahara Enterprise Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10981 Decatur Rd. Ste 4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Philadelphia\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19154-3213\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:FBOUKHORB@GMAIL.COM\"> FBOUKHORB@GMAIL.COM\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 29, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 728927\u003C\u002Fp>\u003Cp>Dear Khalid A. Zaidan:\u003C\u002Fp>\u003Cp>On February 27,2026 through March 16,2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Sahara Enterprise Inc. located at 10981 Decatur Rd., Ste 4, Philadelphia, PA 19154-3213. We also conducted an inspection on November 15, 2018, December 28, 2020, July 28,2022 and September 14,2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response, dated April 07,2026 in which you stated that you will try to learn more on how to prepare FSVP records and also try to get third-party help and prepare FSVP records for the three products. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cp>1. DRY DOUGH MIX (phyllo dough) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>2. CANDY (Turkish delight) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>3. BAKLAVA imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Jananiga Vanniyasingam, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Jananiga.vanniyasingam@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Vanniyasingam via email at Jananiga.vanniyasingam@fda.hhs.gov. Please reference CMS # 728927 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nKhalid A. Zaidan\n\nRecipient Title\n\nOwner\n\nSahara Enterprise Inc.\n\n10981 Decatur Rd. Ste 4\n\nPhiladelphia, PA 19154-3213\n\nUnited States\n\nFBOUKHORB@GMAIL.COM\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nApril 29, 2026\nWARNING LETTER\nRE: CMS# 728927\nDear Khalid A. Zaidan:\nOn February 27,2026 through March 16,2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Sahara Enterprise Inc. located at 10981 Decatur Rd., Ste 4, Philadelphia, PA 19154-3213. We also conducted an inspection on November 15, 2018, December 28, 2020, July 28,2022 and September 14,2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response, dated April 07,2026 in which you stated that you will try to learn more on how to prepare FSVP records and also try to get third-party help and prepare FSVP records for the three products. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\n1. DRY DOUGH MIX (phyllo dough) imported from (b)(4), located in (b)(4).\n2. CANDY (Turkish delight) imported from (b)(4), located in (b)(4).\n3. BAKLAVA imported from (b)(4) located in (b)(4).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Jananiga Vanniyasingam, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Jananiga.vanniyasingam@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Vanniyasingam via email at Jananiga.vanniyasingam@fda.hhs.gov. Please reference CMS # 728927 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Imports","Sahara Enterprise Inc.","sahara-enterprise-inc-728927-04292026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsahara-enterprise-inc-728927-04292026","2026-10-26T08:09:52.86129+00:00","2026-05-19","728927","Khalid A. Zaidan","2026-08-19T04:41:48.104+00:00","2026-04-29",{"id":359,"raw":360,"subject":61,"body_html":364,"body_text":365,"firm_name":366,"letter_id":367,"created_at":350,"fei_number":19,"letter_url":368,"updated_at":369,"action_type":22,"case_status":23,"posted_date":370,"marcs_cms_no":19,"product_type":26,"closeout_date":19,"issuing_office":60,"recipient_name":371,"body_fetched_at":372,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":373,"medical_device_id":19,"response_letter_date":19},74,[361,362,363,60,61,13,13,13],"\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-17T04:00:00Z\">04\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-enterprise-727852-group\">Great Enterprise - Group - Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Phat V. Phung\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great Enterprise - Group - Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2660 Waiwai Loop\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Honolulu\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96819-1992\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 17, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 727852\u003C\u002Fp>\u003Cp>Dear Mr. Phung:\u003C\u002Fp>\u003Cp>On April 2, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Great Enterprise (Group) Inc., located at 2660 Waiwai Loop, Honolulu, HI 96819-1992. We also conducted inspections on April 11 and 24, 2019; January 28 through February 10, 2021; and July 24, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response dated April 15, 2026, in which you stated that you have initiated steps to develop an FSVP program by requesting hazard analysis documents from your suppliers and exploring training options. You also committed to establishing a comprehensive FSVP program and achieving full compliance by your next inspection. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Hoisin Sauce imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Canned Bamboo Shoots Slices imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Rice Stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Rice Stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Rice Stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection you provided the investigator with the following documents: copies of product labels, invoices, Entry Summaries, Certificates of Analysis, a Certificate of Ingredients, a flow chart, a HACCP plan, and third-party food safety certifications including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You told our investigator that you requested these documents from your foreign suppliers. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a).\u003C\u002Fp>\u003Cp>For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to Canned Bamboo Shoots Slices imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 727852 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPhat V. Phung\n\nRecipient Title\n\nPresident\n\nGreat Enterprise - Group - Inc.\n\n2660 Waiwai Loop\n\nHonolulu, HI 96819-1992\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nApril 17, 2026\nWARNING LETTER\nRe: CMS # 727852\nDear Mr. Phung:\nOn April 2, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Great Enterprise (Group) Inc., located at 2660 Waiwai Loop, Honolulu, HI 96819-1992. We also conducted inspections on April 11 and 24, 2019; January 28 through February 10, 2021; and July 24, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response dated April 15, 2026, in which you stated that you have initiated steps to develop an FSVP program by requesting hazard analysis documents from your suppliers and exploring training options. You also committed to establishing a comprehensive FSVP program and achieving full compliance by your next inspection. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\n(b)(4) Hoisin Sauce imported from (b)(4), located in (b)(4).\nCanned Bamboo Shoots Slices imported from (b)(4), located in (b)(4).\n(b)(4) Rice Stick imported from (b)(4), located in (b)(4).\nRice Stick imported from (b)(4), located in (b)(4).\n(b)(4) Rice Stick imported from (b)(4), located in (b)(4).\nDuring our inspection you provided the investigator with the following documents: copies of product labels, invoices, Entry Summaries, Certificates of Analysis, a Certificate of Ingredients, a flow chart, a HACCP plan, and third-party food safety certifications including (b)(4). You told our investigator that you requested these documents from your foreign suppliers. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a).\nFor thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to Canned Bamboo Shoots Slices imported from (b)(4), located in (b)(4) were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 727852 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","Great Enterprise - Group - Inc.","great-enterprise-727852-group","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-enterprise-727852-group","2026-10-26T08:08:49.369676+00:00","2026-06-23","Phat V. Phung","2026-08-19T04:33:08.215+00:00","2026-04-17",{"id":375,"raw":376,"subject":121,"body_html":380,"body_text":381,"firm_name":382,"letter_id":383,"created_at":170,"fei_number":19,"letter_url":384,"updated_at":385,"action_type":22,"case_status":23,"posted_date":386,"marcs_cms_no":387,"product_type":130,"closeout_date":19,"issuing_office":120,"recipient_name":388,"body_fetched_at":389,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":390,"medical_device_id":19,"response_letter_date":19},3433,[377,378,379,120,121,13,13,13],"\u003Ctime datetime=\"2021-03-30T13:20:00Z\">03\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-26T04:00:00Z\">03\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmorin-enterprises-inc-dba-ecig-crib-614011-03262021\">Morin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin Morin, Debra Morin, and Amy Harris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Morin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3027 Coon Rapids Blvd. NW\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coon Rapids\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55433\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ecigcribcsr@gmail.com\"> ecigcribcsr@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 26, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Kevin Morin, Debra Morin, and Amy Harris:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website http:\u002F\u002Fecigcrib.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website http:\u002F\u002Fecigcrib.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: E Cig Crib - Planet of the Grapes E Liquid and E Cig Crib - Cotton Candy E Liquid.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 4,700 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101556, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products c\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at \u003Cspan>(301) 796-9235\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Morin Enterprises Inc.\u003Cbr>\nAttn: Kevin Morin\u003Cbr>\n230 Dewey Str\u003Cbr>\nMankato, MN 56001\u003C\u002Fp>\n\n\u003Cp>Morin Enterprises Inc.\u003Cbr>\nAttn: Kevin Morin\u003Cbr>\n52112 190th Lane\u003Cbr>\nLake Crystal, MN 56055\u003C\u002Fp>\n\n\u003Cp>Morin Enterprises Inc. d\u002Fb\u002Fa E-Cig Crib\u003Cbr>\nAttn: \u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Google LLC\u003Cbr>\ngoogle-cloud-compliance@google.com\u003C\u002Fp>\n\n\u003Cp>Register.com, Inc.\u003Cbr>\nabuse@web.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKevin Morin, Debra Morin, and Amy Harris\n\nMorin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib\n\n3027 Coon Rapids Blvd. NW\n\nCoon Rapids, MN 55433\n\nUnited States\n\necigcribcsr@gmail.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 26, 2021\n\nWARNING LETTER\n\nDear Kevin Morin, Debra Morin, and Amy Harris:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website http:\u002F\u002Fecigcrib.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website http:\u002F\u002Fecigcrib.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: E Cig Crib - Planet of the Grapes E Liquid and E Cig Crib - Cotton Candy E Liquid.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 4,700 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101556, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products c\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nMorin Enterprises Inc.\n\nAttn: Kevin Morin\n\n230 Dewey Str\n\nMankato, MN 56001\n\nMorin Enterprises Inc.\n\nAttn: Kevin Morin\n\n52112 190th Lane\n\nLake Crystal, MN 56055\n\nMorin Enterprises Inc. d\u002Fb\u002Fa E-Cig Crib\n\nAttn: (b)(6)\n\nGoogle LLC\n\ngoogle-cloud-compliance@google.com\n\nRegister.com, Inc.\n\nabuse@web.com","Morin Enterprises Inc. d\u002Fb\u002Fa Ecig Crib","morin-enterprises-inc-dba-ecig-crib-614011-03262021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmorin-enterprises-inc-dba-ecig-crib-614011-03262021","2026-10-26T08:09:27.968041+00:00","2021-03-30","614011","Kevin Morin, Debra Morin, and Amy Harris","2026-08-20T03:15:05.918+00:00","2021-03-26",{"id":392,"raw":393,"subject":207,"body_html":397,"body_text":398,"firm_name":399,"letter_id":400,"created_at":43,"fei_number":19,"letter_url":401,"updated_at":402,"action_type":22,"case_status":23,"posted_date":403,"marcs_cms_no":404,"product_type":49,"closeout_date":19,"issuing_office":36,"recipient_name":405,"body_fetched_at":406,"delivery_method":407,"recipient_title":19,"reference_number":19,"action_taken_date":408,"medical_device_id":19,"response_letter_date":19},1647,[394,395,396,36,207,13,13,13],"\u003Ctime datetime=\"2024-01-30T14:20:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-26T05:00:00Z\">01\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fs-j-international-enterprises-public-company-limited-668482-01262024\">S &amp; J International Enterprises Public Company Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Praj Srichandra\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Factory Division Manager, Board Member of Saha Group\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>S &amp; J International Enterprises Public Company Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>600\u002F4 Moo.11 Sukaphiban 8 Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nongkharm\u003C\u002Fspan>, \u003Cspan>Si Racha\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chon Buri\u003C\u002Fspan> \u003Cspan>20230\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-17\u003C\u002Fp>\n\n\u003Cp>January 26, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Srichandra:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, S &amp; J International Enterprises Public Company Limited, FEI 3005979923, at 600\u002F4 Moo.11 Sukaphiban 8 Road, Nongkharm, Si Racha, from July 17 to July 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Furthermore, during the inspection you delayed or limited access to or copying of records requested. Due to your delay and limiting access to or copying of records during the inspection, the drug products you manufacture are also deemed adulterated within the meaning of section 501(j) of the FD&amp;C Act, 21 U.S.C. 351(j).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight and control over your drug manufacturing operations. Specifically, your QU did not implement adequate controls to prevent the alteration of production records, to ensure the complete documentation of laboratory preparation, and to ensure the review of raw analytical data. For example, production staff are able to alter master batch records, including modifying batch formulations and other parameters or formulations before printing. Laboratory sample preparation is not documented, and weight print-outs are not retained. Lastly, your QU only reviews analytical results entered into your enterprise system and does not review raw analytical data before releasing quarantined materials or finished drug products.\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\n\t\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\n\t\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\n\t\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You recorded production data on laminated sheets using erasable markers that could be easily altered or lost. These logs were used to record \u003Cstrong>(b)(4)\u003C\u002Fstrong> weight verification checks for balances and scales, room cleaning checklists, employee health and hygiene checks, operator shoe cleaning, pest control checks, facility and equipment checks, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature and humidity monitoring in manufacturing areas. You stated that these temporary records are scanned and retained. However, you could not provide the permanent version of these records and stated that only production staff and production supervisors, and not the QU, have access to the scanned sheets and logs. Without adequate and complete batch records, you cannot assure the uniformity of your drug products from batch to batch and may impact your ability to adequately investigate any product deviations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Delaying, Denying, Limiting, or Refusing a Drug Inspection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You delayed and limited access to or copying of records requested during the inspection. During the inspection, our investigator provided a list of requested documents and made numerous repeat requests during the inspection for these documents. Yet, your firm only provided or allowed access to a limited number of documents.\u003C\u002Fp>\n\n\u003Cp>For example, upon request for the current labeling for your United States (U.S.) drug product, you provided a single photograph of the primary and secondary drug product packaging on the last day of the inspection, which was of poor quality and not legible.\u003C\u002Fp>\n\n\u003Cp>Additionally, upon request for a list of all laboratory non-conformances and investigations during the inspection, your staff initially stated that there were no out-of-trend, out-of-specification (OOS), incidents, non-conformances, or investigations, and provided blank logs for years 2021-2023. However, later during the inspection, our investigator observed logs for these years on an electronic drive that contained non-conformance report numbers, dates, descriptions, and close-out dates, and appeared to include a raw material OOS entry for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the active ingredient in your U.S. drug product. Only after discovery by our investigator were these logs provided to our investigator.\u003C\u002Fp>\n\n\u003Cp>When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&amp;C Act. See FDA’s guidance document \u003Cem>Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on January 23, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at S &amp; J International Enterprises Public Company Limited, 600\u002F4 Moo.11 Sukaphiban 8 Road, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005979923 and ATTN: Christina Capacci-Daniel.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Response provided by email on December 19, 2023 following the July 17 to July 21, 2023 inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Praj Srichandra\n\nRecipient Title\n\nFactory Division Manager, Board Member of Saha Group\n\nS & J International Enterprises Public Company Limited\n\n600\u002F4 Moo.11 Sukaphiban 8 Road\n\nNongkharm, Si Racha\n\nChon Buri 20230\n\nThailand\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWarning Letter 320-24-17\n\nJanuary 26, 2024\n\nDear Mr. Srichandra:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, S & J International Enterprises Public Company Limited, FEI 3005979923, at 600\u002F4 Moo.11 Sukaphiban 8 Road, Nongkharm, Si Racha, from July 17 to July 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nFurthermore, during the inspection you delayed or limited access to or copying of records requested. Due to your delay and limiting access to or copying of records during the inspection, the drug products you manufacture are also deemed adulterated within the meaning of section 501(j) of the FD&C Act, 21 U.S.C. 351(j).\n\nWe reviewed your response1 to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight and control over your drug manufacturing operations. Specifically, your QU did not implement adequate controls to prevent the alteration of production records, to ensure the complete documentation of laboratory preparation, and to ensure the review of raw analytical data. For example, production staff are able to alter master batch records, including modifying batch formulations and other parameters or formulations before printing. Laboratory sample preparation is not documented, and weight print-outs are not retained. Lastly, your QU only reviews analytical results entered into your enterprise system and does not review raw analytical data before releasing quarantined materials or finished drug products.\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\nA determination of whether procedures used by your firm are robust and appropriate.\n\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\nA complete and final review of each batch and its related information before the QU disposition decision.\n\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n2. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\n\nYou recorded production data on laminated sheets using erasable markers that could be easily altered or lost. These logs were used to record (b)(4) weight verification checks for balances and scales, room cleaning checklists, employee health and hygiene checks, operator shoe cleaning, pest control checks, facility and equipment checks, and (b)(4) temperature and humidity monitoring in manufacturing areas. You stated that these temporary records are scanned and retained. However, you could not provide the permanent version of these records and stated that only production staff and production supervisors, and not the QU, have access to the scanned sheets and logs. Without adequate and complete batch records, you cannot assure the uniformity of your drug products from batch to batch and may impact your ability to adequately investigate any product deviations.\n\nIn response to this letter, provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nDelaying, Denying, Limiting, or Refusing a Drug Inspection\n\nYou delayed and limited access to or copying of records requested during the inspection. During the inspection, our investigator provided a list of requested documents and made numerous repeat requests during the inspection for these documents. Yet, your firm only provided or allowed access to a limited number of documents.\n\nFor example, upon request for the current labeling for your United States (U.S.) drug product, you provided a single photograph of the primary and secondary drug product packaging on the last day of the inspection, which was of poor quality and not legible.\n\nAdditionally, upon request for a list of all laboratory non-conformances and investigations during the inspection, your staff initially stated that there were no out-of-trend, out-of-specification (OOS), incidents, non-conformances, or investigations, and provided blank logs for years 2021-2023. However, later during the inspection, our investigator observed logs for these years on an electronic drive that contained non-conformance report numbers, dates, descriptions, and close-out dates, and appeared to include a raw material OOS entry for (b)(4), the active ingredient in your U.S. drug product. Only after discovery by our investigator were these logs provided to our investigator.\n\nWhen an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance document Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on January 23, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at S & J International Enterprises Public Company Limited, 600\u002F4 Moo.11 Sukaphiban 8 Road, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005979923 and ATTN: Christina Capacci-Daniel.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n_________________\n\n1 Response provided by email on December 19, 2023 following the July 17 to July 21, 2023 inspection.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","S & J International Enterprises Public Company Limited","s-j-international-enterprises-public-company-limited-668482-01262024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fs-j-international-enterprises-public-company-limited-668482-01262024","2026-10-26T08:09:52.159638+00:00","2024-01-30","668482","Mr. Praj Srichandra","2026-08-20T00:21:40.309+00:00","VIA UPS","2024-01-26",48,{"510k":411,"classification":412,"enforcement":413,"event":414,"event_backfill":415,"pma":416,"warning_letter":417},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]